

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055538
Article Type:	Original research
Date Submitted by the Author:	16-Jul-2021
Complete List of Authors:	Zhang, Xiaochao; The Second Xiangya Hospital, Central South University, Dermatology; Hunan Key Laboratory of Medical Epigenomics Zhang, Suhan; The Second Xiangya Hospital, Central South University, Dermatology; Hunan Key Laboratory of Medical Epigenomics Wu, Ruifang; The Second Xiangya Hospital, Central South University, Dermatology; Hunan Key Laboratory of Medical Epigenomics Zhang, Peng; The Second Xiangya Hospital, Central South University, Dermatology; Hunan Key Laboratory of Medical Epigenomics Su, Yuwen; The Second Xiangya Hospital, Central South University, Dermatology; Hunan Key Laboratory of Medical Epigenomics Li, Siying; The Second Xiangya Hospital, Central South University, Dermatology; Hunan Key Laboratory of Medical Epigenomics
Keywords:	Psoriasis < DERMATOLOGY, Thyroid disease < DIABETES & ENDOCRINOLOGY, IMMUNOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5 The prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis
6
7
8
9

10 Xiaochao Zhang^{1,2#}, Suhan Zhang^{1,2#}, Ruifang Wu^{1,2}, Peng Zhang^{1,2}, Yuwen Su^{1,2}, Siying
11
12 Li^{1,2}
13
14
15
16

- 17 1. Department of Dermatology, The Second Xiangya Hospital, Central South University
18
19 2. Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, 410011, China
20
21

22 # Both two authors contributed equally to this work.
23
24
25

26 Correspondence to: Yuwen Su, Department of Dermatology, The Second Xiangya
27
28 Hospital, Central South University, 139th Renmin Middle Road, Furong district,
29
30 Changsha, Hunan, 410011, China
31
32

33 Phone: 086-13755116633 Email: suyuwen1963@csu.edu.cn
34
35

36 Siying Li, Department of Dermatology, The Second Xiangya Hospital, Central South
37
38 University, 139th Renmin Middle Road, Furong district, Changsha, Hunan, 410011,
39
40 China
41
42

43 Phone: 086-18975625824 Email: 2204130711@csu.edu.cn
44
45
46

47 Running title: A meta-analysis of AITD and psoriasis
48
49
50

51 Abstract

52
53

54 **Objective** Psoriasis is a chronic inflammatory disease with autoimmune etiology. A
55
56 possible link between psoriasis and autoimmune thyroid disease (AITD) has been
57
58 suggested in some studies with inconsistent findings. This meta-analysis aims to
59
60

1
2
3
4
5 determine the association between psoriasis and AITD and to provide better advice for
6
7 the management of psoriasis.
8
9

10 **Methods** The electronic search was conducted through PubMed, EMBASE,
11 PubMed, EMBASE, and the Cochrane Library. Two independent reviewers screened the
12 articles, and then the third independent reviewer conducted the final review. The Mantel-
13 Haenszel method was applied to perform the meta-analysis using the Stata 15.0 software.
14
15 Odds ratio (OR) and 95% confidence intervals (CI) were pooled to compare the
16 prevalence of AITD in psoriasis and control groups.
17
18
19
20
21
22

23 **Results** Ten available studies with data on 253,173 patients with psoriasis and
24 1,376,073 controls were included. Meta-analysis showed that patients with psoriasis had
25 a higher prevalence of AITD (OR = 1.46, 95% CI: 1.28 - 1.67, Z = 5.51, $p < 0.001$),
26 especially loss-of-function disorder of the thyroid gland. Both TgAb positive rate (OR =
27 1.76, 95% CI: 1.28 - 2.43, Z = 3.47, $p = 0.001$) and TPOAb positive rate (OR = 1.77, 95%
28 CI: 1.31 - 2.40, Z = 3.68, $p < 0.001$) were also increased in the psoriasis group compared
29 to the control group.
30
31
32
33
34
35
36
37
38
39

40 **Conclusions** Our study indicated that the comorbid prevalence of AITD was
41 significantly increased in patients with psoriasis. Thyroid-related examinations should be
42 considered as a part of routine evaluations in patients with psoriasis.
43
44
45
46

47 PROSPERO registration number CRD42020206005

48
49 Keywords: Psoriasis, Thyroid, Immunology
50
51
52
53

54 **Strengths and limitations of this study**

55
56 This is the first meta-analysis focusing on the risk of AITD for psoriasis patients, which
57 included hypothyroidism, hyperthyroidism, subclinical hypothyroidism, subclinical
58
59
60

1
2
3
4
5 hyperthyroidism, Hashimoto's thyroiditis, Graves' disease, TgAb and TPOAb.
6

7
8 All studies included had moderate to high quality and representative, and published in
9
10 recent years.
11

12 The heterogeneity in the pooled data cannot be ignored, and couldn't improve by
13
14 subgroup analysis.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

Psoriasis is a chronic inflammatory disease with autoimmune etiology, affecting approximately 125 million people around the world^{1 2}. The skin lesions of psoriasis occur mainly on the scalp, trunk, and exterior surfaces of the limbs, and manifest as erythema, plaques, and scales³. Apart from the impaired appearance and intense pruritus of the skin lesions, various comorbidities have a significant impact on the quality of life in patients with psoriasis^{4 5}. Among the comorbidities, autoimmune thyroid disease (AITD) has been characterized in patients with psoriasis. For patients with psoriasis who also develop complications, their management requires extra attention⁶. Therefore, understanding the risk of other diseases on psoriasis has important clinical significance.

Autoimmune thyroid disease (AITD) is an inflammatory disease of the thyroid gland with the presence of thyroid autoantibodies, lymphocytic infiltration of thyroid parenchyma, and even thyroid dysfunction⁷. Graves' disease (GD) and Hashimoto's thyroiditis (HT) are the two main clinical subtypes of AITD. GD is characterized by hyperthyroidism and the presence of thyroid-stimulating hormone receptor antibodies (TRAb) in serum, while HT is characterized by hypothyroidism and the presence of thyroid peroxidase antibodies (TPOAb) or Thyroglobulin antibodies (TgAb) in serum⁸.

Psoriasis and AITD share some common pathophysiological features, such as Th1-predominant adaptive immune reaction⁷. Hence, the relationship between AITD and psoriasis has been hypothesized and studied. In 2006, Antonelli *et al.* first reported that the prevalence of AITD in patients with psoriatic arthritis was significantly higher than in the general population⁹. However, the study reported by Tsai *et al.* pointed that the

1
2
3
4 association between psoriasis and AITD was limited¹⁰. In recent years, several
5
6 observational studies regarding the association between psoriasis and AITD were
7
8 published in succession, but the results of the studies were inconsistent¹¹⁻¹⁶. In addition,
9
10 Karadag *et al.* reported that the commonly administered acitretin treatment for psoriasis
11
12 system treatment affects the levels of free T4 (thyroid hormone)¹⁷. To address this
13
14 discrepancy, we designed and performed a meta-analysis with the existing evidence to
15
16 assess the relationship between psoriasis and AITD, and to provide guidance on clinical
17
18 management of psoriasis.
19
20
21
22
23

24 **METHODS**

25 **Search strategy**

26
27
28
29
30 The literature search was conducted through PubMed, EMBASE, and the
31
32 Cochrane Library for relevant studies published before August 24th, 2020. Detailed
33
34 literature-search strategies of the databases are presented in Table 1.
35
36

37 **Inclusion and exclusion criteria**

38
39
40 The inclusion criteria for the studies included in our analysis were the following:
41
42 (1) The prevalence of AITD in patients with psoriasis/psoriatic arthritis and non-
43
44 psoriasis were studied; (2) The study was a cohort study, case-control study, or cross-
45
46 sectional study; (3) The observed indicators were at least one of the following outcomes:
47
48 the prevalence of hypothyroidism, hyperthyroidism, HT, GD, or the positive rate of
49
50 TPOAb, TgAb, or TRAb; (4) The number of patients with psoriasis and the control
51
52 group should be over 50. Drug-related studies, animal studies, reviews, and conference
53
54 abstracts were excluded from our analysis.
55
56
57
58
59
60

Data extraction

The specific process for analyzing the studies generated from the search was as follows: record screening and data extraction were performed by two independent authors (XC Zhang and SH Zhang) according to the above retrieval strategy. The following information in the included studies were extracted: the name of the first author, year of publication, country of origin, study design, sample size, the definition of psoriasis and AITD, gender ratio, and mean age.

Quality assessment

The Newcastle-Ottawa Scale (NOS)¹⁸ was used to assess the quality of the included cohort and case-control studies, and the tools recommended by the Agency for Healthcare Research and Quality (AHRQ)¹⁹ were used for the cross-sectional studies.

Data synthesis and analysis

The meta-analysis was performed using the Stata 15.0 software. We used the Odds ratio (OR) and 95% Confidence Intervals (CI) to describe the differences between groups. The statistical difference was considered significant when $p < 0.05$. The Mantel-Haenszel method was used for data analysis. The inconsistency index (I^2) was used to evaluate heterogeneity as follows: $I^2 \leq 25\%$, no heterogeneity; $25\% \leq I^2 \leq 50\%$, mild heterogeneity; $50\% < I^2 \leq 75\%$, moderate heterogeneity; $I^2 > 75\%$, severe heterogeneity. A fixed effects model was applied if $I^2 \leq 50\%$ and the random effects model was applied when $I^2 > 50\%$. Publication bias was assessed by Funnel chart and Egger's test (Publication bias was considered when $p < 0.05$). Sensitivity Analysis was performed to assess the stability of the meta-analysis by omitting one study in each turn. The flow

1
2
3
4 chart was drawn in Adobe Illustrator, and the forest charts, funnel charts, and Egger's
5
6 test charts were drawn by Stata 15.0 software.
7

8 9 **Patient and public involvement**

10
11 There were not patients or the public involved in this review.
12
13

14 **RESULTS**

15 16 17 **Search results**

18
19 After removing duplicate results, we identified 3217 published studies in the initial
20
21 search. After screening the titles and abstracts, 16 studies underwent further screening.
22
23 After full-text screening, 10 studies^{2 9-16 20} that met the inclusion criteria were included
24
25 in the final analysis (figure. 1).
26
27
28
29

30 **Study characteristics**

31
32 The basic characteristics of the included studies are shown in Tables 2 and 3. A
33
34 total of 253,173 patients with psoriasis and 1,376,073 control patients were included in
35
36 the analysis. Four studies were from Asia, and six were from Europe and North America.
37
38 Two of the studies were cohort studies, seven were case-controlled studies, and one was
39
40 a cross-sectional study.
41
42
43
44

45 **Prevalence of AITD in patients with psoriasis**

46
47 Ten studies provided available data on the prevalence of AITD in patients with
48
49 psoriasis. The meta-analysis showed that patients with psoriasis had a higher prevalence
50
51 of AITD than the controls (OR = 1.46, 95% CI: 1.28 - 1.67, Z = 5.51, $p < 0.001$), and
52
53 the heterogeneity was moderate ($I^2 = 70.6%$, $p < 0.001$). Subgroup analyses by study
54
55 type indicated that the prevalence of AITD was significantly higher in the case-control
56
57
58
59
60

1
2
3
4 study strata (OR = 1.40, 95% CI: 1.18 - 1.67, $Z = 3.88$, $p < 0.001$) and the cross-section
5
6 study strata (OR = 2.11, 95% CI: 1.55-2.88, $Z = 4.72$, $p < 0.001$), but not in the cohort
7
8 study strata (OR = 1.55, 95% CI: 0.95 - 2.54, $Z = 1.76$, $p = 0.079$) (figure. 2).

11 **Sensitivity analysis and publication bias**

12
13
14 The combined effects after removal of any one study were all within the
15
16 confidence interval of the total combined effect (figure. 3A). Therefore, the results of
17
18 the analysis were reliable and stable. The funnel chart for the publication bias is shown
19
20 in Figure. 3B. The results of Egger's test suggested no significant publication bias was
21
22 evident ($p = 0.066$, figure. 3C).

27 **Psoriasis and thyroid function status**

28
29
30 Patients with psoriasis had a significantly higher prevalence of hypothyroidism
31
32 than the controls (OR = 1.44, 95% CI: 1.34 - 1.55, $Z = 9.44$, $p < 0.001$) and no significant
33
34 heterogeneity was observed ($I^2 = 0.0\%$, $p = 0.679$). Patients with psoriasis had a higher
35
36 prevalence of hyperthyroidism than the controls (OR = 1.20, 95% CI: 1.11 - 1.30, $Z =$
37
38 4.76 , $p < 0.001$). No significant heterogeneity was observed ($I^2 = 0.0\%$, $p = 0.512$, figure.
39
40 4A-B).

41
42
43 Additionally, a higher prevalence of subclinical hypothyroidism and subclinical
44
45 hyperthyroidism was observed in patients with psoriasis compared with the controls
46
47 (Subclinical hypothyroidism: OR = 2.17, 95% CI: 0.27 - 17.72, $Z = 0.72$, $p = 0.470$.
48
49 Subclinical hyperthyroidism: OR = 2.66, 95% CI: 0.74 - 9.56, $Z = 1.50$, $p = 0.132$).
50
51 However, the difference was not statistically significant (Supplementary figure. 1 A-
52
53
54
55
56
57
58
59
60 B).

Psoriasis and specific autoimmune thyroid diseases

The prevalence of HT in patients with psoriasis and in the controls was 0.209% and 0.199%, respectively, while the prevalence of GD in patients with psoriasis and in the controls was 0.443% and 0.405%, respectively. The prevalence of HT was significantly higher in patients with psoriasis than the controls (OR = 1.68, 95% CI: 1.48 - 1.92, $Z = 7.86$, $p < 0.001$) and the heterogeneity was mild ($I^2 = 37.3\%$, $p = 0.188$). However, the heterogeneity of GD in these studies was too severe ($I^2 = 92.7\%$, $p < 0.001$), so the OR (OR = 1.02, 95% CI: 0.65 - 1.60, $Z = 0.07$, $p = 0.943$) had no reference value (figure. 4C, figure. 5A).

Psoriasis and thyroid serological antibodies

The positive rate of TgAb was significantly higher in patients with psoriasis than the controls (OR = 1.76, 95% CI: 1.28 - 2.43, $Z = 3.47$, $p = 0.001$) and no significant heterogeneity was observed ($I^2 = 14.3\%$, $p = 0.323$). The positive rate of TPOAb was significantly higher in patients with psoriasis than the controls (OR = 1.77, 95% CI: 1.31 - 2.40, $Z = 3.68$, $p < 0.001$) and the heterogeneity was mild ($I^2 = 45.0\%$, $p = 0.122$). Since no studies have been published about the positive rate of TRAb in patients with psoriasis, only TgAb and TPOAb were analyzed (figure. 5B-C).

Heterogeneity analysis

According to the results of the funnel plot, three studies outside the funnel plot were removed and the meta-analysis was conducted again. The results of the second analysis also showed that patients with psoriasis had a higher prevalence of AITD than the controls (OR = 1.30, CI: 1.18-1.43, $Z = 5.46$, $p < 0.001$) and the heterogeneity was

1
2
3
4 mild ($I^2 = 46.8\%$, $p = 0.080$) The source of heterogeneity in the study of Antonelli *et*
5
6 *al.* was that all the patients were patients with psoriatic arthritis, and the prevalence of
7
8 AITD in patients with psoriatic arthritis may be higher than that of patients with
9
10 psoriasis²¹. The source of heterogeneity in the study by Peluso *et al.* may have been due
11
12 to the control group bring comprised of hospital staff rather than the general population².
13
14 The source of heterogeneity in the study of Kiguradze *et al.* may lie in the fact that it
15
16 was a cross-sectional study¹³. These three studies were not excluded because they had
17
18 little effect on the final results of the analysis.
19
20
21
22
23

24 **DISCUSSION**

25
26
27 To our knowledge, this is the first meta-analysis focusing on the risk of AITD for
28
29 psoriasis patients. While the study by Khan SR *et al.* is the first meta-analysis of studies
30
31 on the association between AITD and the risk of psoriasis incidence²². We summarized
32
33 all available evidence on the association between psoriasis and AITD. Our meta-
34
35 analysis found that the prevalence of AITD, and particularly HT, was higher in patients
36
37 with psoriasis than the control individuals. Additionally, elevated positive rates of
38
39 TgAb and TPOAb were also observed in patients with psoriasis. Collectively, a positive
40
41 association between psoriatic disease and AITD can be indicated. Considering that
42
43 psoriasis is a type of discosmetic dermatosis that is easy to be concerned about, patients
44
45 with psoriasis are more likely to be active about seeing a doctor regarding their
46
47 condition than patients with AITD. As such, we recommend that patients with psoriasis
48
49 receive a thyroid-related examination at their first visit, as well at regular follow-ups to
50
51 assess thyroid function. By promoting early diagnosis and treatment of AITD, patients
52
53
54
55
56
57
58
59
60

1
2
3
4 may be able to avoid thyroid dysfunction.
5

6 7 **Main findings**

8
9 The primary finding of this meta-analysis is the increased prevalence of AITD in
10 the population of patients with psoriasis. However, moderate heterogeneity was
11 observed. We hypothesize that the inconsistency of the study designs was the major
12 source of heterogeneity. When the subgroup analysis according to different study
13 designs was conducted, the heterogeneity in each subgroup was reduced, and the results
14 remained positive. According to the definition of the study designs, an accurate cause-
15 effect relationship can only be demonstrated in the cohort studies. In the present study,
16 three types of study designs were included in the meta-analysis, including cohort, case
17 controlled, and cross-sectional studies. Therefore, the results should be interpreted with
18 caution. Additionally, it has been demonstrated that the prevalence of HT in patients
19 with psoriasis is elevated compared with the controls. HT, a main clinical subtype of
20 AITD, is generally accompanied by hypothyroidism. An elevated frequency of
21 hypothyroidism was also observed in patients with psoriasis. Taken together, the
22 current data indicates that psoriasis may be closely associated with the loss-of-function
23 disorder of the thyroid gland.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Common pathogenesis of psoriasis and AITD**

49
50 Abnormal immunological reaction and underlying genetic risk are two
51 indispensable factors responsible for triggering psoriasis and AITD. These two diseases
52 share some autoimmune processes and susceptibility genes, which may explain the
53 concurrence of psoriasis and AITD. The predominant Th1 immune reaction has been
54
55
56
57
58
59
60

1
2
3
4 observed in patients with psoriasis^{23 24}, such as Th1 infiltration in involved tissues, and
5
6 high serum levels of Th1-prototype chemokines and cytokines (TNF- α , IFN- γ , and
7
8 CXCL10), all of which are present in AITD²⁵⁻²⁷. Additionally, Th17-mediated immune
9
10 disorder has also been observed in psoriasis and AITD^{28 29}. Several predisposing genetic
11
12 alleles or regions are shared by the two diseases. For example, the genetic data from
13
14 265 families with two or more autoimmune disorders have shown that the PTPN22-
15
16 R620W allele has a remarkable association with HT and a mild association with
17
18 psoriasis^{30 31}. Additionally, other SNP variations in the PTPN22 gene have been
19
20 demonstrated to be indicators for evaluating the risk of psoriasis³². IL12B has been
21
22 generally recognized as a psoriasis susceptibility gene³³, an upstream variation of which
23
24 was found to affect the phenotype of AITD in men³⁴.

31 32 **Implications for practice**

33
34
35 It has been reported that the administration of acitretin, a common drug for the
36
37 treatment of psoriasis, can lead to the reduction of free T4 (thyroid hormone) levels in
38
39 patients with psoriasis¹⁷. The finding suggests that patients with psoriasis should have
40
41 thyroid-related examinations regularly while undergoing acitretin treatment. In addition,
42
43 propylthiouracil (PTU), a drug used to inhibit thyroid hormone synthesis, has been
44
45 found to be effective in the treatment of psoriasis³⁵. Based on the above findings, it is
46
47 recommended that the treatment options be adjusted once patients with psoriasis are
48
49 diagnosed with comorbid AITD.
50
51
52
53
54

55 56 **Limitations**

57
58 This meta-analysis contains several limitations. First, the meta-analysis included
59
60

1
2
3
4 studies with different study designs. Given this, we conducted a subgroup analysis of
5
6 each study design. However, the heterogeneity did not improve, suggesting that
7
8 different study designs were not the main source of heterogeneity. Second, the
9
10 diagnostic criteria of psoriasis and AITD, gender ratio, and course of disease varied
11
12 from study to study, but meta-analysis regression was meaningless due to the small
13
14 number of articles included in our study. Additionally, the included studies were
15
16 conducted in different regions, so the influence of geographical location, living habits,
17
18 and drug use may also affect the prevalence of AITD in the population, resulting in
19
20 discordance. Therefore, further large-scale and high-quality prospective studies are still
21
22 required to validate our findings.
23
24
25
26
27
28

29 30 **CONCLUSIONS**

31
32 The present meta-analysis revealed that AITD was more prevalent in patients with
33
34 psoriasis than in the general population, especially loss-of-function disorder of the
35
36 thyroid gland. Moreover, patients with psoriasis were found to have elevated positive
37
38 rates of TPOAb and TgAb compared to the control individuals. Accordingly, we
39
40 recommend that every dermatologist be conscious of this association and suggest those
41
42 thyroid-related examinations, such as thyroid function test and analysis of thyroid
43
44 antibodies, be included in the routine tests for patients with psoriasis.
45
46
47
48
49
50

51
52
53 **Contributors** XZ and SZ carried out the extraction of reference data, meta-analysis,
54
55 and wrote manuscripts, RW and PZ supported and assisted the manuscripts, YS and SL
56
57 reviewed and suggested the manuscripts. All authors were involved in finalizing the
58
59
60

1
2
3
4 manuscript.

5
6 **Funding**

7
8
9 This work was supported by grants from the National Natural Science Foundation of
10
11 China [No. 81872534 to Yuwen Su].

12
13
14 **Competing interests** None declared.

15
16
17 **Patient consent for publication** Not required.

18
19 **Ethics approval** As this is a meta-analysis ethics approval was not required.

20
21
22 **Provenance and peer review** Not commissioned; externally peer reviewed.

23
24
25 **Data availability statement** Data are available in a public, open access repository.

26
27
28 No additional data are available.

29
30 **Acknowledgments**

31
32 The authors thank AiMi Academic Services (www.aimieditor.com) for English
33
34 language editing and review services.

35
36
37 **ORCID iD**

38
39
40 Yuwen Su <https://orcid.org/0000-0001-9918-1830>
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Griffiths CEM, Van Der Walt JM, Ashcroft DM, *et al.* The global state of psoriasis disease epidemiology: a workshop report. *Br J Dermatol* 2017;177(1):e4-e7.
2. Peluso R, Lupoli GA, Del Puente A, *et al.* Prevalence of thyroid autoimmunity in patients with spondyloarthropathies. *J Rheumatol* 2011;38(7):1371-7.
3. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis* 2005;64 Suppl 2:ii18-23; discussion ii24-5.
4. Dauden E, Castaneda S, Suarez C, *et al.* Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. *J Eur Acad Dermatol Venereol* 2013;27(11):1387-404.
5. Schaefer CP, Cappelleri JC, Cheng R, *et al.* Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. *J Am Acad Dermatol* 2015;73(4):585-93.e3.
6. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. *J Am Acad Dermatol* 2019;80(1):27-40.
7. Antonelli A, Ferrari SM, Corrado A, *et al.* Autoimmune thyroid disorders. *Autoimmun Rev* 2015;14(2):174-80.
8. Hesarghatta Shyamasunder A, Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves' disease. *Clin Endocrinol (Oxf)* 2017;86(5):652-57.
9. Antonelli A, Delle Sedie A, Fallahi P, *et al.* High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. *J Rheumatol* 2006;33(10):2026-8.
10. Tsai TF, Wang TS, Hung ST, *et al.* Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci* 2011;63(1):40-6.
11. Fallahi P, Ferrari SM, Ruffilli I, *et al.* Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. *Immunol Res* 2017;65(3):681-86.
12. Haddad A, Ashkenazi RI, Bitterman H, *et al.* Endocrine Comorbidities in Patients with Psoriatic Arthritis: A Population-based Case-controlled Study. *J Rheumatol* 2017;44(6):786-90.
13. Kiguradze T, Bruins FM, Guido N, *et al.* Evidence for the association of Hashimoto's thyroiditis with psoriasis: a cross-sectional retrospective study. *Int J Dermatol* 2017;56(5):553-56.
14. Vassilatou E, Papadavid E, Papastamatakis P, *et al.* No association of psoriasis with autoimmune thyroiditis. *J Eur Acad Dermatol Venereol* 2017;31(1):102-06.
15. Alidrisi HA, Al Hamdi K, Mansour AA. Is There Any Association Between Psoriasis and Hashimoto's Thyroiditis? *Cureus* 2019;11(3):e4269.
16. Wang SH, Wang J, Lin YS, *et al.* Increased risk for incident thyroid diseases in people with psoriatic disease: A cohort study. *J Am Acad Dermatol* 2019;80(4):1006-12.
17. Karadag AS, Ozlu E, Kostek O, *et al.* Effect of low-dose acitretin treatment on pituitary hormones in psoriasis vulgaris: A retrospective study. *Indian J Dermatol Venereol Leprol* 2019;85(3):300-04.
18. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in Newcastle-analyses. Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in Newcastle-analyses. 2019.
19. AHRQ Evidence Reports. Secondary AHRQ Evidence Reports 2004.
20. Wu JJ, Nguyen TU, Poon KY, *et al.* The association of psoriasis with autoimmune diseases. *J Am Acad Dermatol* 2012;67(5):924-30.
21. Vastarella M, Megna M, Lupoli GA, *et al.* Is there any association between psoriasis, psoriatic

- 1
2
3 arthritis and thyroid autoimmunity? *Australas J Dermatol* 2020.
- 4 22. Khan SR, Bano A, Wakkee M, *et al.* The association of autoimmune thyroid disease (AITD) with
5 psoriatic disease: a prospective cohort study, systematic review and meta-analysis. *Eur J Endocrinol*
6 2017;177(4):347-59.
- 7 23. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. *Cell Mol Immunol*
8 2012;9(4):302-9.
- 9 24. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. *Annu Rev Immunol* 2014;32:227-
10 55.
- 11 25. Antonelli A, Ferrari SM, Giuggioli D, *et al.* Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune
12 diseases. *Autoimmun Rev* 2014;13(3):272-80.
- 13 26. Nanba T, Watanabe M, Inoue N, *et al.* Increases of the Th1/Th2 cell ratio in severe Hashimoto's
14 disease and in the proportion of Th17 cells in intractable Graves' disease. *Thyroid* 2009;19(5):495-
15 501.
- 16 27. Peng S, Li C, Wang X, *et al.* Increased Toll-Like Receptors Activity and TLR Ligands in Patients with
17 Autoimmune Thyroid Diseases. *Front Immunol* 2016;7:578.
- 18 28. Hansel A, Gunther C, Ingwersen J, *et al.* Human slan (6-sulfo LacNAc) dendritic cells are inflammatory
19 dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. *J Allergy Clin Immunol*
20 2011;127(3):787-94.e1-9.
- 21 29. Vitales-Noyola M, Ramos-Levi AM, Martinez-Hernandez R, *et al.* Pathogenic Th17 and Th22 cells are
22 increased in patients with autoimmune thyroid disorders. *Endocrine* 2017;57(3):409-17.
- 23 30. Criswell LA, Pfeiffer KA, Lum RF, *et al.* Analysis of families in the multiple autoimmune disease
24 genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple
25 autoimmune phenotypes. *Am J Hum Genet* 2005;76(4):561-71.
- 26 31. Wang H, Wang Z, Rani PL, *et al.* Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes
27 demonstrates shared pathogenesis between psoriasis and diabetes. *Exp Dermatol*
28 2017;26(11):1112-17.
- 29 32. Li Y, Liao W, Chang M, *et al.* Further genetic evidence for three psoriasis-risk genes: ADAM33,
30 CDKAL1, and PTPN22. *J Invest Dermatol* 2009;129(3):629-34.
- 31 33. Cargill M, Schrodi SJ, Chang M, *et al.* A large-scale genetic association study confirms IL12B and leads
32 to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 2007;80(2):273-90.
- 33 34. Walsh JP, Berry J, Liu S, *et al.* The clinical presentation of autoimmune thyroid disease in men is
34 associated with IL12B genotype. *Clin Endocrinol (Oxf)* 2011;74(4):508-12.
- 35 35. Gnanaraj P, Malligarjunan H, Dayalan H, *et al.* Therapeutic efficacy and safety of propylthiouracil in
36 psoriasis: an open-label study. *Indian J Dermatol Venereol Leprol* 2011;77(6):673-6.
- 37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Figure legend:**

54
55
56 Figure 1 Flowchart for study screening

57
58 Figure 2 Forest plot of the association between psoriasis and autoimmune thyroid
59
60

disease

Figure 3 Sensitivity analysis and publication bias

Figure 4 A: Forest plots of psoriasis and hypothyroidism B: Forest plots of psoriasis and hyperthyroidism C: Forest plots of psoriasis and HT

Figure 5 A: Forest plots of psoriasis and GD B: Forest plots of psoriasis and TgAb C: Forest plots of psoriasis and TPOAb

Database	Retrieval strategy
PubMed	((((((((((Thyroid[Title/Abstract]) OR (Thyroiditis[Title/Abstract])) OR (Hashimoto Thyroiditis[Title/Abstract])) OR (Graves Disease[Title/Abstract])) OR (Hyperthyroidism[Title/Abstract])) OR (Hypothyroidism[Title/Abstract])) OR (TgAb[Title/Abstract])) OR (TPOAb[Title/Abstract])) OR (TRAb[Title/Abstract])) OR (Endocrine Comorbidities[Title/Abstract])) OR (Autoimmune diseases[Title/Abstract])) AND ((psoriasis[Title/Abstract]) OR (psoriatic[Title/Abstract]))
Cochrane	((Psoriasis) OR psoriatic) OR Pustulosis of Palms) AND (((((((Thyroid) OR Thyroiditis) OR Thyroiditides) OR Hashimoto Disease) OR Graves Disease) OR Hyperthyroidism) OR Hypothyroidism)). Then chose "Trials"
Embase	(thyroid:ab,ti OR thyroiditis:ab,ti OR 'hashimoto thyroiditis':ab,ti OR 'graves disease':ab,ti OR hyperthyroidism:ab,ti OR hypothyroidism:ab,ti OR tgab:ab,ti OR tpoab:ab,ti OR trab:ab,ti OR 'endocrine comorbidities':ab,ti OR 'autoimmune diseases':ab,ti) AND (psoriasis:ab,ti OR psoriatic:ab,ti)

Table 1 Database source and retrieval strategy.

TPOAb: Thyroid peroxidase antibody; TgAb: Thyroglobulin antibody; TRAb: Thyroid stimulating hormone receptor antibody.

Study (Author)	Year	Country	Study design	No.Patients	No.Controls	Patients, % male	Patients, mean age
Antonelli <i>et al.</i>	2006	Italy	Case-control	80	400	45	57
Tsai <i>et al.</i>	2011	China	Case-control	51800	207200	61.6	46.4
Peluso <i>et al.</i>	2011	Italy	Case-control	108	318	47.2	39.9

<i>al.</i>				control				
Wu <i>et al.</i>	2012	American	Case-	25341	126705	51.6	48.9	
			control					
Vassilatou <i>et al.</i>	2017	Greece	Case-	114	286	50.9	52.7	
			control					
Kiguradze <i>et al.</i>	2017	Greece	Cross-	9654	846961	NA	NA	
			sectional					
Haddad <i>et al.</i>	2017	Israel	Case-	3161	31610	46.6	58.4	
			control					
Fallahi <i>et al.</i>	2017	Italy	Cohort	97	97	47.4	56	
Alidrisi <i>et al.</i>	2019	Iraq	Case-	56	54	41.1	43.05	
			control					
Wang <i>et al.</i>	2019	China	Cohort	162842	162842	59.35	45	


Table 2 Characteristics of the included studies

Study (Author)	Definition of psoriasis	Definition of AITD	NOS score
Antonelli <i>et al.</i>	PsA was diagnosed by the criteria of Vasey and Espinoza	AITD was diagnosed by serum levels of thyroid stimulating hormone and TgAb and TPOAb	7
Tsai <i>et al.</i>	Ps was diagnosed by clinical examination	AITD was diagnosed by clinical examination	6
Peluso <i>et al.</i>	PsA was diagnosed by the Classification of Psoriatic Arthritis study group criteria	AITD was diagnosed by serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL, and Thyroid ultrasonography	7
Wu <i>et al.</i>	Ps was diagnosed by clinical diagnosis	AITD was diagnosed by clinical diagnosis	7
Vassilatou <i>et al.</i>	Ps was diagnosed by clinical examination	AITD was diagnosed by serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL	7
Kiguradze <i>et al.</i>	Ps was diagnosed by clinical diagnosis	AITD was diagnosed by clinical diagnosis	6
Haddad <i>et al.</i>	Ps was diagnosed by clinical diagnosis	AITD was diagnosed by clinical diagnosis	6
Fallahi <i>et al.</i>	PsA was diagnosed by the criteria of Vasey and Espinoza	AITD was diagnosed by serum levels of TgAb or TPOAb > 100 IU/mL	6
Alidrisi <i>et al.</i>	Ps was diagnosed by clinical	AITD was diagnosed by serum levels of	6

1			
2			
3	<i>al.</i>	diagnosis	TgAb > 115 IU/mL or TPOAb > 34 IU/mL
4			
5	Wang <i>et al.</i>	Ps was diagnosed by at least 2 outpatient visits or 1 hospital admission	AITD was diagnosed by at least 2 outpatient visits or 1 hospital admission
6			8
7			
8			
9			

Table 3 Characteristics of the included studies (2)


For peer review only



Flowchart for study screening




209x152mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Forest plot of the association between psoriasis and autoimmune thyroid disease

215x189mm (300 x 300 DPI)



Sensitivity analysis and publication bias

141x150mm (300 x 300 DPI)



A: Forest plots of psoriasis and hypothyroidism B: Forest plots of psoriasis and hyperthyroidism C: Forest plots of psoriasis and HT

117x195mm (300 x 300 DPI)





Fig. 5 A: Forest plots of psoriasis and GD B: Forest plots of psoriasis and TgAb C: Forest plots of psoriasis and TPOAb

124x237mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



117x129mm (300 x 300 DPI)



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	2
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	5, Table 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Table 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	6, Figure 1
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	6, Figure 1
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Table 3
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Table 2
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	7 - 10
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Figure 1
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	6
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Figure 2 - 5
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	6
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	7, 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Figure 3
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	8, Figure 3
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	8, Figure 3



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	×
Study characteristics	17	Cite each included study and present its characteristics.	Table 2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	×
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2 - 5
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	9
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	8 - 9
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Figure 3
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Figure 3
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Figure 3
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	11
	23b	Discuss any limitations of the evidence included in the review.	12
	23c	Discuss any limitations of the review processes used.	12
	23d	Discuss implications of the results for practice, policy, and future research.	13
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	×
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	×
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	14
Competing interests	26	Declare any competing interests of review authors.	14
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Table 1



PRISMA 2020 Checklist

For more information, visit: <http://www.prisma-statement.org/>

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

BMJ Open

The prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055538.R1
Article Type:	Original research
Date Submitted by the Author:	02-Dec-2021
Complete List of Authors:	Zhang, Xiaochao; Central South University, Dermatology; Second Xiangya Hospital Department of Dermatology Zhang, Suhan; Central South University, Dermatology; Second Xiangya Hospital Department of Dermatology Wu, Ruifang; Central South University, Dermatology; Second Xiangya Hospital, Dermatology Li, Siying; Central South University, Dermatology; Second Xiangya Hospital, Dermatology Su, Yuwen; Central South University, Dermatology; Second Xiangya Hospital, Dermatology Zhang, Peng; Central South University, Dermatology; Second Xiangya Hospital, Dermatology
Primary Subject Heading:	Dermatology
Secondary Subject Heading:	Dermatology, Immunology (including allergy)
Keywords:	Thyroid disease < DIABETES & ENDOCRINOLOGY, IMMUNOLOGY, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5 The prevalence of autoimmune thyroid disease in patients with psoriasis: a
6 meta-analysis
7
8
9
10

11
12 Xiaochao Zhang^{1#}, Suhan Zhang^{1#}, Ruifang Wu¹, Siying Li¹, Yuwen Su^{1*}, Peng
13 Zhang^{1*}
14

15
16
17 1. Department of Dermatology, The Second Xiangya Hospital, Central South
18 University
19

20
21 # Both two authors contributed equally to this work.
22
23

24
25
26 * Correspondence to: Yuwen Su, Department of Dermatology, The Second Xiangya
27 Hospital, Central South University, 139th Renmin Middle Road, Furong district,
28 Changsha, Hunan, 410011, China
29

30
31 Phone: 086-13755116633 Email: suyuwen1963@csu.edu.cn
32

33
34
35 Peng Zhang, Department of Dermatology, The Second Xiangya Hospital, Central South
36 University, 139th Renmin Middle Road, Furong district, Changsha, Hunan, 410011,
37 China
38
39

40
41 Phone: 086-15874291251 Email: zhangpeng@csu.edu.cn
42

43
44 Running title: A meta-analysis of AITD and psoriasis
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective Psoriasis is a chronic inflammatory disease with autoimmune etiology. A possible link between psoriasis and autoimmune thyroid disease (AITD) has been suggested in some studies with inconsistent findings. This meta-analysis aims to determine the association between psoriasis and AITD.

Design A Meta-analysis of observational studies.

Data sources PubMed, EMBASE, Scopus, and the Cochrane Library were searched up to November 1st, 2021.

Eligibility criteria for selecting studies We included non-randomized studies, each with over 50 cases in every group, focusing on the rate of comorbidity between psoriasis and AITD.

Data extraction and synthesis Two independent reviewers screened the articles and extracted data. The restricted maximum-likelihood was applied to perform the meta-analysis. Odds ratio (OR) and 95% confidence intervals (CI) were pooled to compare the prevalence of AITD in psoriasis and control groups. Heterogeneity was assessed with I^2 statistic. The Newcastle-Ottawa Scale (NOS) and Agency for Healthcare Research and Quality (AHRQ) were applied for quality assessment. The risk of bias was assessed with ROBINS-I.

Results Eleven available studies with data on 253,313 patients with psoriasis and 1,376,533 controls were included. Meta-analysis showed that patients with psoriasis had a higher prevalence of AITD (OR = 1.76, 95% CI: 1.35 - 2.28, $Z = 4.25$, $p < 0.01$), especially loss-of-function disorder of the thyroid gland. Both TgAb positive rate (OR = 1.98, 95% CI: 1.27 - 3.10, $Z = 3.00$, $p < 0.01$) and TPOAb positive rate (OR = 2.15, 95% CI: 1.31 - 3.52, $Z = 3.05$, $p < 0.01$) were also increased in the psoriasis group compared

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

to the control group.

Conclusions Our study indicates that the rate of co-occurring AITD was significantly increased in patients with psoriasis. It suggests that the increased risk of AITD should be concerned in patients with psoriasis.

PROSPERO registration number CRD42020206005

Keywords: Psoriasis, Thyroid, Immunology

Strengths and limitations of this study

This is the first meta-analysis focusing on the risk of AITD for psoriasis patients, which included hypothyroidism, hyperthyroidism, subclinical hypothyroidism, subclinical hyperthyroidism, Hashimoto's thyroiditis, Graves' disease, TgAb positivity and TPOAb positivity.

All studies included were of moderate to high quality and were representative. All studies were published in recent years.

The heterogeneity in the pooled data cannot be ignored, and was not improved by subgroup analysis. However, meta-regression analysis identified the differences of sample size and scope of research on AITD among these studies as the potential sources of heterogeneity.

INTRODUCTION

Psoriasis is a chronic inflammatory disease with autoimmune etiology, affecting approximately 125 million people around the world.¹ The skin lesions of psoriasis occur mainly on the scalp, trunk, and exterior surfaces of the limbs, and manifest as erythema, plaques, and scales.² Apart from the impaired appearance and intense pruritus of the skin lesions, various comorbidities have a significant impact on the quality of life in patients with psoriasis.^{3 4} Among the comorbidities, autoimmune thyroid disease (AITD) has been characterized in patients with psoriasis. For patients with psoriasis who also develop complications, their management requires extra attention.⁵ Therefore, understanding the risk of other diseases on psoriasis has important clinical significance.

Autoimmune thyroid disease (AITD) is an inflammatory disease of the thyroid gland with the presence of thyroid autoantibodies, lymphocytic infiltration of thyroid parenchyma, and even thyroid dysfunction.⁶ Graves' disease (GD) and Hashimoto's thyroiditis (HT) are the two main clinical subtypes of AITD. GD is characterized by hyperthyroidism and the presence of thyroid-stimulating hormone receptor antibodies (TRAb) in serum, while HT is characterized by hypothyroidism and the presence of thyroid peroxidase antibodies (TPOAb) or Thyroglobulin antibodies (TgAb) in serum.⁷

Psoriasis and AITD share some common pathophysiological features, such as Th1-predominant adaptive immune reaction.⁶ Hence, the relationship between AITD and psoriasis has been hypothesized and studied. In 2006, Antonelli *et al.* first

1
2
3
4 reported that the prevalence of AITD in patients with psoriatic arthritis was
5
6 significantly higher than in the general population.⁸ However, the study reported by
7
8 Tsai *et al.*⁹ pointed that the association between psoriasis and AITD was limited. In
9
10 recent years, several observational studies regarding the association between psoriasis
11
12 and AITD were published in succession, but the results of the studies were
13
14 inconsistent.¹⁰⁻¹⁶ In addition, Karadag *et al.* reported that the commonly administered
15
16 acitretin treatment for psoriasis system treatment affects the levels of free T4 (thyroid
17
18 hormone).¹⁷ To address this discrepancy, we designed and performed a meta-analysis
19
20 with the existing evidence to assess the relationship between psoriasis and AITD and
21
22 provide guidance on the clinical management of psoriasis.
23
24
25
26
27
28

29 30 **METHODS**

31 32 **Search strategy**

33
34 The literature search was conducted through PubMed, EMBASE, Scopus, and
35
36 the Cochrane Library for relevant studies published before November 1st, 2021.
37
38 Detailed literature-search strategies of the databases are presented in Table 1.
39
40

41 42 **Inclusion and exclusion criteria**

43
44 The inclusion criteria for the studies included in our analysis were the following:
45
46 (1) The prevalence of AITD in patients with psoriasis/psoriatic arthritis and
47
48 non-psoriasis were studied; (2) The study was a cohort study, case-control study, or
49
50 cross-sectional study; (3) The observed indicators were at least one of the following
51
52 outcomes: the prevalence of hypothyroidism, hyperthyroidism, HT, GD, or the
53
54 positive rate of TPOAb, TgAb, or TRAb; (4) The number of patients with psoriasis
55
56
57
58
59
60

1
2
3
4 and the control group should be over 50. Drug-related studies, animal studies, reviews,
5
6 and conference abstracts were excluded from our analysis.
7
8

9 **Data extraction**

10
11 The specific process for analyzing the studies generated from the search was as
12
13 follows: record screening and data extraction were performed by two independent
14
15 authors (X Zhang and S Zhang) according to the above retrieval strategy. In case of
16
17 dispute, the third author(R Wu) would reassess and reach an agreed decision after
18
19 discussion. The following information in the included studies was extracted: the name
20
21 of the first author, year of publication, country of origin, study design, sample size,
22
23 the definition of psoriasis and AITD, gender ratio, and mean age.
24
25
26
27
28
29

30 **Quality assessment**

31
32 The Newcastle-Ottawa Scale (NOS)¹⁸ was used to assess the quality of the
33
34 included cohort and case-control studies. The quality of the study was scored by three
35
36 dimensions: selection, comparability, and exposure/outcome. Studies that achieved
37
38 0-3, 4-6, 7-9 scores were considered of low, moderate and high qualities respectively.
39
40 Additionally, the tools recommended by the Agency for Healthcare Research and
41
42 Quality (AHRQ)¹⁹ were used for the cross-sectional studies. Eleven items were
43
44 included in AHRQ. The study would get one point if the answer “Yes”, otherwise no
45
46 point was got. Studies achieved: 0-3, 4-7, and 8-11 points were considered of low,
47
48 moderate and high qualities respectively. Moreover, the ROBINS-I was used to assess
49
50 the risk of bias.²⁰ The assessments were carried by two authors (X Zhang and S
51
52 Zhang), and checked by the third author(R Wu).
53
54
55
56
57
58
59
60

1
2
3
4 The meta-analysis was performed using the Stata 16.0 software. We used the
5
6 odds ratio (OR) and 95% confidence intervals (CI) to describe the differences
7
8 between groups. The statistical difference was considered significant when $p < 0.05$.
9
10 The prediction interval was used to explore the prevalence of AITD in individuals
11
12 with psoriasis. The I^2 statistic was used to evaluate heterogeneity as follows: $I^2 \leq 25\%$,
13
14 no heterogeneity; $25\% \leq I^2 \leq 50\%$, mild heterogeneity; $50\% < I^2 \leq 75\%$, moderate
15
16 heterogeneity; $I^2 > 75\%$, severe heterogeneity. The random effects model was applied
17
18 throughout the analyses. Publication bias was assessed by funnel plot and Egger's test
19
20 (Publication bias was considered when $p < 0.1$). Sensitivity analysis was performed to
21
22 assess the stability of the meta-analysis by omitting one study in each turn. Univariate
23
24 meta-regression analysis was used to investigate the sources of heterogeneity. The
25
26 flow chart was drawn in Adobe Illustrator, and the forest plots, funnel plots, and
27
28 Egger's test charts were drawn by Stata 16.0 software.
29
30
31
32
33
34
35
36
37

38 **Patient and public involvement**

39
40 There were not patients or the public involved in this review.
41
42

43 **RESULTS**

44 **Search results**

45
46
47
48 After removing duplicate results, we identified 6380 published studies in the
49
50 initial search: 6377 studies were included by searching through databases and three
51
52 studies were harvested by manually searching the references of relevant studies. After
53
54 screening the titles and abstracts, the remaining 42 studies underwent further full-text
55
56 screening. Eventually, 11 studies^{8-16 21 22} that met the inclusion criteria were included
57
58
59
60

1
2
3
4 in the final analysis (figure. 1).
5

6 **Study characteristics**

7
8
9 The basic characteristics of the included studies are shown in Tables 2 and 3. A
10 total of 253,313 patients with psoriasis and 1,376,533 control patients were included
11 in the analysis. Two of the studies were cohort studies, eight were case-controlled
12 studies, and one was a cross-sectional study.
13
14
15
16
17

18 **Quality of studies**

19
20 Overall, five studies were of high qualities and six of moderate ones (Table 3). In
21 the studies checked with NOS (n=10), five studies were considered of moderate
22 qualities because the control groups were not from the same community. The only
23 cross-sectional study checked with AHRQ was a moderate quality study due to
24 confounding controlling was not clear. Based on ROBINS-I, all included studies had
25 moderate risk in overall bias (Table 4).
26
27
28
29
30
31
32
33
34
35
36

37 **Prevalence of AITD in patients with psoriasis**

38
39
40 Eleven studies provided available data on the prevalence of AITD in patients
41 with psoriasis. The meta-analysis showed that patients with psoriasis had a higher
42 prevalence of AITD than the controls (OR = 1.76, 95% CI: 1.35 - 2.28, Z = 4.25, *p*
43 <0.01). The prediction interval ranged from 0.79 to 2.73, and the heterogeneity was
44 severe ($I^2 = 92.72\%$).
45
46
47
48
49
50
51
52

53 **Heterogeneity analysis**

54
55
56 To investigate potential sources of heterogeneity, we firstly performed a
57 subgroup analysis by types of study design. The high rate of comorbidity between
58
59
60

1
2
3
4 psoriasis and AITD was also observed in the cross-sectional study strata (OR = 2.12,
5
6 95% CI: 1.55 - 2.89), and in the case-control study strata (OR = 1.75, 95% CI: 1.23 -
7
8 2.48, $Z = 3.14$, $p < 0.01$) but with heterogeneity remaining severe (figure. 2), which
9
10 indicated that inconsistency of the study designs was not the source of high
11
12 heterogeneity.
13
14
15

16
17 We further conducted a meta-regression analysis to explore the reason for
18
19 between-study heterogeneity. Seven variables were included in the regression model,
20
21 covering average age, sex ratio, nation (China or other counties), race (Caucasian or
22
23 non-Caucasian), sample size, clinical types of psoriasis (psoriasis vulgaris or psoriatic
24
25 arthritis), and scope of research on AITD (all studies were divided into two categories:
26
27 the one focusing on the loss-of-function disorder of the thyroid gland alone; another
28
29 one focusing on both the loss-of-function disorder and hyperfunction disorder of the
30
31 thyroid gland). When the criterion was set as $p < 0.1$, sample size ($\beta = -0.40$, $S.E. =$
32
33 0.20 , $p = 0.07$) and scope of research on AITD ($\beta = 0.45$, $S.E. = 0.15$, $p = 0.02$) were
34
35 the potential sources of high heterogeneity.
36
37
38
39
40
41
42

43 Besides, we removed three studies^{8 13 21} outside the funnel plot and then
44
45 conducted the meta-analysis again. The results of the reanalysis also showed that
46
47 patients with psoriasis had a higher prevalence of AITD than the controls (OR = 1.34,
48
49 CI: 1.20-1.50, $Z = 5.07$, $p < 0.01$), but with moderate heterogeneity ($I^2 = 57.30\%$). The
50
51 results indicated that these three studies might also contribute to on severe
52
53 heterogeneity of previous analysis. The source of heterogeneity in the study of
54
55 Antonelli *et al.* was that all the patients were patients with psoriatic arthritis,⁸ and the
56
57
58
59
60

1
2
3
4 prevalence of AITD in patients with psoriatic arthritis may be higher than that of
5
6 patients with psoriasis.²³ The source of heterogeneity in the study by Peluso *et al.* may
7
8 have been due to the control group being comprised of hospital staff rather than the
9
10 general population.²¹ The source of heterogeneity in the study of Kiguradze *et al.* may
11
12 lie in the fact that it was a cross-sectional study.¹³ These three studies were not
13
14 excluded because they had little effect on the final results of the analysis.
15
16
17
18

19 **Sensitivity analysis and publication bias**

20
21
22 Omission of either of the included studies did not significantly change the
23
24 confidence interval of the combined effect (figure. 3A). Therefore, the results of the
25
26 analysis were reliable and stable. The funnel plot for the publication bias is shown in
27
28 figure. 3B. The results of Egger's test showed significant publication bias ($p = 0.036$,
29
30 figure. 3C). There was a possibility of exaggerating the association between psoriasis
31
32 and AITD.
33
34
35
36
37

38 **Psoriasis and thyroid function status**

39
40 Patients with psoriasis had a higher prevalence of hypothyroidism than the
41
42 controls (OR = 1.21, 95% CI: 1.12 - 1.30, $Z = 4.80$, $p < 0.01$) and no significant
43
44 heterogeneity was observed ($I^2 = 0.00\%$). Patients with psoriasis had a higher
45
46 prevalence of hyperthyroidism than the controls (OR = 1.20, 95% CI: 1.12 - 1.30,
47
48 $Z = 4.78$, $p < 0.01$) and no significant heterogeneity was observed ($I^2 = 0.00\%$, figure.
49
50
51
52
53
54
55
56
57
58
59
60
4A-B).

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

(Subclinical hypothyroidism: OR = 2.24, 95% CI: 0.26 - 19.13, Z = 0.74, $p = 0.46$).

Subclinical hyperthyroidism: OR = 2.66, 95% CI: 0.70 - 10.07, Z = 1.44, $p = 0.15$).

However, the difference was not statistically significant (Supplementary figure. 1 A-B).

Psoriasis and specific autoimmune thyroid diseases

The prevalence of HT in patients with psoriasis and the controls was 0.215% and 0.199%, respectively. In comparison, the prevalence of GD in patients with psoriasis and the controls was 0.443% and 0.405%, respectively. The prevalence of HT was significantly higher in patients with psoriasis than the controls (OR = 1.88, 95% CI: 1.50 - 2.35, Z = 5.47, $p < 0.01$) and the heterogeneity was moderate ($I^2 = 55.98\%$). The prevalence of GD was also higher in patients with psoriasis than the controls (OR = 1.02, 95% CI: 0.65 - 1.60, Z = 0.07, $p = 0.94$) and the heterogeneity was severe ($I^2 = 92.78\%$). However, the difference was not statistically significant (figure. 4C, figure. 5A).

Psoriasis and thyroid serological antibodies

No studies provided data on the positive rate of TRAb in patients with psoriasis, so we only included TgAb and TPOAb in the meta-analysis (figure. 5B-C). The positive rate of TgAb was significantly higher in patients with psoriasis than the controls (OR = 1.98, 95% CI: 1.27 - 3.10, Z = 3.00, $p < 0.01$) and the heterogeneity was mild ($I^2 = 41.54\%$). The positive rate of TPOAb was significantly higher in patients with psoriasis than the controls (OR = 2.15, 95% CI: 1.31 - 3.52, Z = 3.05, $p < 0.01$) and the heterogeneity was moderate ($I^2 = 56.27\%$).

DISCUSSION

To our knowledge, this is the first meta-analysis focusing on the risk of AITD for psoriasis patients. The study by Khan *et al.* is the first meta-analysis of studies on the association between AITD and the incidence risk of psoriasis.²⁴ By summarizing all available evidence on the association between psoriasis and AITD, we found that the prevalence of AITD, particularly HT, was higher in patients with psoriasis than the control individuals. Additionally, elevated positive rates of TgAb and TPOAb were also observed in patients with psoriasis. As psoriasis is a type of discosmetic dermatosis and therefore likely to be of concern, patients with psoriasis are more likely to be active about seeing a doctor regarding their condition than patients with AITD. As such, we recommend that patients with psoriasis receive a thyroid-related examination when they have suspicious AITD-related symptoms. By promoting early diagnosis and treatment of AITD, patients may be able to avoid thyroid dysfunction.

Main findings

The primary finding of this meta-analysis is that the prevalence of AITD is increased in patients with psoriasis compared with the general population. However, severe heterogeneity was observed. In order to determine whether or not the inconsistency of the study designs was the primary source of heterogeneity, the subgroup analysis based on different study designs was conducted. However, the heterogeneity was not limited by subgroup analysis; hence the heterogeneity in this meta-analysis was not caused by inconsistency of the study design. Through further meta-regression analysis, we found that the differences in sample size and scope of

1
2
3
4 research on AITD among these studies might explain the high level of between-study
5
6 heterogeneity. Furthermore, the heterogeneity was improved when we focused on the
7
8 link of psoriasis with specific clinical characters of AITD, such as hypothyroidism,
9
10 hyperthyroidism, and the positivity rate of autoantibodies.
11
12

13
14 According to the definition of the study designs, an accurate cause-effect
15
16 relationship can only be demonstrated in cohort studies. The present study included
17
18 three types of study designs, including cohort, case-controlled, and cross-sectional
19
20 studies. Therefore, the results should be interpreted with caution. Additionally, it has
21
22 been demonstrated that the prevalence of HT in patients with psoriasis is elevated
23
24 compared with the controls. HT, a main clinical subtype of AITD, is generally
25
26 accompanied by hypothyroidism. An elevated frequency of hypothyroidism was also
27
28 observed in patients with psoriasis. Taken together, the current data indicates that
29
30 psoriasis may be closely associated with the loss-of-function disorder of the thyroid
31
32 gland.
33
34
35
36
37
38

39 40 **Common pathogenesis of psoriasis and AITD**

41
42 Both Abnormal immunological reactions and underlying genetic risk can
43
44 contribute to the pathogenesis of psoriasis and AITD.^{25 26} These two diseases share
45
46 some autoimmune processes and susceptibility genes, which may explain the
47
48 concurrence of psoriasis and AITD. The predominant Th1 immune reaction has been
49
50 observed in patients with psoriasis,^{27 28} such as Th1 infiltration in involved tissues,
51
52 and high serum levels of Th1-prototype chemokines and cytokines (TNF- α , IFN- γ ,
53
54 and CXCL10), all of which are present in AITD.²⁹⁻³² Additionally, Th17-mediated
55
56
57
58
59
60

1
2
3
4 immune disorder has also been observed in psoriasis and AITD.^{33 34} The two diseases
5
6 share several predisposing genetic alleles or regions. For example, the genetic data
7
8 from 265 families with two or more autoimmune disorders have shown that the
9
10 PTPN22-R620W allele has a remarkable association with HT and a mild association
11
12 with psoriasis.³⁵ Additionally, other SNP variations in the PTPN22 gene have been
13
14 demonstrated to be indicators for evaluating the risk of psoriasis.^{36 37} IL12B has been
15
16 generally recognized as a psoriasis susceptibility gene,³⁸ an upstream variation of
17
18 which affects the phenotype of AITD in men.³⁹

24 **Implications for practice**

25
26
27 Owing to no access to the information on drug application not provided by
28
29 original researches, drug exposure may be a source of residual confounding in the
30
31 present study and a potential risk factor for concurrence of psoriasis and AITD, apart
32
33 from the reasons mentioned above. β -blocker, used to control thyrotoxicosis-related
34
35 symptoms, has been implicated in induction or exacerbation of psoriasis.^{40 41} In
36
37 addition, it has been reported that the administration of acitretin, a common drug for
38
39 the treatment of psoriasis, can lead to the reduction of free T4 (thyroid hormone)
40
41 levels in patients with psoriasis.¹⁷ Therefore, once the patients develop suspicious
42
43 symptoms after these treatments, diagnostic investigation and intervention should be
44
45 considered as early as possible to avoid the exacerbation. On the other hand, the
46
47 treatment for AITD and psoriasis can be mutually beneficial. For example,
48
49 propylthiouracil (PTU), a drug used to inhibit thyroid hormone synthesis, has been
50
51 effective in the treatment of psoriasis.⁴² Based on the above findings, it is
52
53
54
55
56
57
58
59
60

1
2
3
4 recommended that the treatment options be adjusted once patients with psoriasis are
5
6 diagnosed with comorbid AITD.
7
8

9 **Limitations**

10
11 There are several limitations to this meta-analysis. First, the meta-analysis
12 included studies with different study designs. Given this, we conducted a subgroup
13 analysis of each study design, which also showed that the patients with psoriasis had
14 an increased prevalence of AITD in the cross-sectional study strata and the
15 case-control study strata. Second, there is considerable heterogeneity in the present
16 study. Subgroup analysis and meta-regression analysis helped us to identify the
17 potential sources of the heterogeneity. However, there are likely to be other unknown
18 reasons responsible for the heterogeneity. Thirdly, the lack of information on drug
19 application made drug exposure a confounding factor. Therefore, further large-scale
20 and high-quality prospective studies are still required to validate our findings.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **CONCLUSIONS**

38
39 The present meta-analysis revealed that AITD was more prevalent in patients
40 with psoriasis than in the general population, especially loss-of-function disorder of
41 the thyroid gland. Moreover, patients with psoriasis were found to have elevated
42 positive rates of TPOAb and TgAb compared to the control individuals. Accordingly,
43 we recommend that every dermatologist be conscious of this association and suggest
44 necessary examinations and intervention be considered as soon as possible when
45 patients with psoriasis have suspicious AITD-related symptoms.
46
47
48
49
50
51
52
53
54
55
56

57
58 **Contributors** XZ and SZ carried out the extraction of reference data, meta-analysis,
59
60

1
2
3
4 and wrote manuscripts, RW and PZ supported and assisted the manuscripts, YS and
5
6
7 SL reviewed and suggested the manuscripts. All authors were involved in finalizing
8
9 the manuscript.
10

11 **Funding**

12
13
14 This work was supported by grants from the National Natural Science Foundation
15
16 of China (No. 81872534 to Yuwen Su) and the Fundamental Research Funds for the
17
18 Central Universities of Central South University (No. 2019zzts905).
19
20
21

22 **Competing interests** None declared.
23

24 **Patient consent for publication** Not required.
25

26 **Ethics approval** As this is a meta-analysis ethics approval was not required.
27
28

29 **Provenance and peer review** Not commissioned; externally peer reviewed.
30
31

32 **Data availability statement** All data relevant to the study are included in the article.
33
34

35 **Acknowledgments** Not required.
36
37

38 **ORCID iD**

39
40 Yuwen Su <https://orcid.org/0000-0001-9918-1830>
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Griffiths CEM, Van Der Walt JM, Ashcroft DM, *et al.* The global state of psoriasis disease epidemiology: a workshop report. *Br J Dermatol* 2017;177(1):e4-e7.
2. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis* 2005;64 Suppl 2:ii18-23; discussion ii24-5.
3. Dauden E, Castaneda S, Suarez C, *et al.* Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. *J Eur Acad Dermatol Venereol* 2013;27(11):1387-404.
4. Schaefer CP, Cappelleri JC, Cheng R, *et al.* Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. *J Am Acad Dermatol* 2015;73(4):585-93.e3.
5. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. *J Am Acad Dermatol* 2019;80(1):27-40.
6. Antonelli A, Ferrari SM, Corrado A, *et al.* Autoimmune thyroid disorders. *Autoimmun Rev* 2015;14(2):174-80.
7. Hesarghatta Shyamasunder A, Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves' disease. *Clin Endocrinol (Oxf)* 2017;86(5):652-57.
8. Antonelli A, Delle Sedie A, Fallahi P, *et al.* High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. *J Rheumatol* 2006;33(10):2026-8.
9. Tsai TF, Wang TS, Hung ST, *et al.* Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci* 2011;63(1):40-6.
10. Alidrisi HA, Al Hamdi K, Mansour AA. Is There Any Association Between Psoriasis and Hashimoto's Thyroiditis? *Cureus* 2019;11(3):e4269.
11. Fallahi P, Ferrari SM, Ruffilli I, *et al.* Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. *Immunol Res* 2017;65(3):681-86.
12. Haddad A, Ashkenazi RI, Bitterman H, *et al.* Endocrine Comorbidities in Patients with Psoriatic Arthritis: A Population-based Case-controlled Study. *J Rheumatol* 2017;44(6):786-90.
13. Kiguradze T, Bruins FM, Guido N, *et al.* Evidence for the association of Hashimoto's thyroiditis with psoriasis: a cross-sectional retrospective study. *Int J Dermatol* 2017;56(5):553-56.
14. Valduga JaG, Rebeiko LB, Skare TL. Prevalence of Hashimoto's thyroiditis in psoriasis patients. *Rev Assoc Med Bras (1992)* 2021;67(1):52-57.
15. Vassilatou E, Papadavid E, Papastamatakis P, *et al.* No association of psoriasis with autoimmune thyroiditis. *J Eur Acad Dermatol Venereol* 2017;31(1):102-06.
16. Wang SH, Wang J, Lin YS, *et al.* Increased risk for incident thyroid diseases in people with psoriatic disease: A cohort study. *J Am Acad Dermatol* 2019;80(4):1006-12.
17. Karadag AS, Ozlu E, Kostek O, *et al.* Effect of low-dose acitretin treatment on pituitary hormones in psoriasis vulgaris: A retrospective study. *Indian J Dermatol Venereol Leprol* 2019;85(3):300-04.
18. Wells. G, Shea. B, O'connell. D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in Newcastle-analyses. 11th November 2021 2019. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Rostom. A, Dubé. C, Cranney. A, *et al.* AHRQ Evidence Reports. 11th November 2021 2004. <https://www.ncbi.nlm.nih.gov/books/NBK35156/>.
20. Sterne JA, Hernán MA, Reeves BC, *et al.* ROBINS-I: a tool for assessing risk of bias in

- 1
2
3 non-randomised studies of interventions. *BMJ (Clinical research ed)* 2016;355:i4919.
- 4
5 21. Peluso R, Lupoli GA, Del Puente A, *et al.* Prevalence of thyroid autoimmunity in patients with
6 spondyloarthropathies. *J Rheumatol* 2011;38(7):1371-7.
- 7
8 22. Wu JJ, Nguyen TU, Poon KY, *et al.* The association of psoriasis with autoimmune diseases. *J Am*
9 *Acad Dermatol* 2012;67(5):924-30.
- 10
11 23. Vastarella M, Megna M, Lupoli GA, *et al.* Is there any association between psoriasis, psoriatic
12 arthritis and thyroid autoimmunity? *Australas J Dermatol* 2020.
- 13
14 24. Khan SR, Bano A, Wakkee M, *et al.* The association of autoimmune thyroid disease (AITD) with
15 psoriatic disease: a prospective cohort study, systematic review and meta-analysis. *Eur J*
16 *Endocrinol* 2017;177(4):347-59.
- 17
18 25. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annual review of pathology* 2012;7:385-422.
- 19
20 26. Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of
21 pathogenesis. *Nature reviews Endocrinology* 2013;9(5):277-87.
- 22
23 27. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. *Cell Mol Immunol*
24 2012;9(4):302-9.
- 25
26 28. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. *Annu Rev Immunol*
27 2014;32:227-55.
- 28
29 29. Antonelli A, Ferrari SM, Giuggioli D, *et al.* Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune
30 diseases. *Autoimmun Rev* 2014;13(3):272-80.
- 31
32 30. Ruffilli I, Ragusa F, Benvenga S, *et al.* Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity.
33 *Front Endocrinol (Lausanne)* 2017;8:139.
- 34
35 31. Nanba T, Watanabe M, Inoue N, *et al.* Increases of the Th1/Th2 cell ratio in severe Hashimoto's
36 disease and in the proportion of Th17 cells in intractable Graves' disease. *Thyroid*
37 2009;19(5):495-501.
- 38
39 32. Peng S, Li C, Wang X, *et al.* Increased Toll-Like Receptors Activity and TLR Ligands in Patients with
40 Autoimmune Thyroid Diseases. *Front Immunol* 2016;7:578.
- 41
42 33. Hansel A, Gunther C, Ingwersen J, *et al.* Human slan (6-sulfo LacNAc) dendritic cells are
43 inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. *J*
44 *Allergy Clin Immunol* 2011;127(3):787-94.e1-9.
- 45
46 34. Vitales-Noyola M, Ramos-Levi AM, Martinez-Hernandez R, *et al.* Pathogenic Th17 and Th22 cells
47 are increased in patients with autoimmune thyroid disorders. *Endocrine* 2017;57(3):409-17.
- 48
49 35. Criswell LA, Pfeiffer KA, Lum RF, *et al.* Analysis of families in the multiple autoimmune disease
50 genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple
51 autoimmune phenotypes. *Am J Hum Genet* 2005;76(4):561-71.
- 52
53 36. Li Y, Liao W, Chang M, *et al.* Further genetic evidence for three psoriasis-risk genes: ADAM33,
54 CDKAL1, and PTPN22. *J Invest Dermatol* 2009;129(3):629-34.
- 55
56 37. Wang H, Wang Z, Rani PL, *et al.* Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk
57 genes demonstrates shared pathogenesis between psoriasis and diabetes. *Exp Dermatol*
58 2017;26(11):1112-17.
- 59
60 38. Cargill M, Schrodi SJ, Chang M, *et al.* A large-scale genetic association study confirms IL12B and
leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 2007;80(2):273-90.
39. Walsh JP, Berry J, Liu S, *et al.* The clinical presentation of autoimmune thyroid disease in men is
associated with IL12B genotype. *Clin Endocrinol (Oxf)* 2011;74(4):508-12.
40. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. *Psoriasis (Auckl)*

1
2
3 2017;7:87-94.

4 41. Mcdermott MT. Hyperthyroidism. *Annals of internal medicine* 2020;172(7):ITC49-ITC64.

5
6 42. Gnanaraj P, Malligarjunan H, Dayalan H, *et al.* Therapeutic efficacy and safety of propylthiouracil
7 in psoriasis: an open-label study. *Indian J Dermatol Venereol Leprol* 2011;77(6):673-6.
8
9

10
11
12 **Figure legend:**

13
14 Figure 1 Flowchart for study screening

15
16
17 Figure 2 Forest plot of the association between psoriasis and autoimmune thyroid
18 disease
19

20
21
22 Figure 3 Sensitivity analysis and publication bias

23
24
25 Figure 4 A: Forest plots of psoriasis and hypothyroidism B: Forest plots of psoriasis
26 and hyperthyroidism C: Forest plots of psoriasis and HT
27

28
29
30 Figure 5 A: Forest plots of psoriasis and GD B: Forest plots of psoriasis and TgAb C:
31 Forest plots of psoriasis and TPOAb
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Database	Retrieval strategy
PubMed	((((((((((Thyroid[Title/Abstract]) OR (Thyroiditis[Title/Abstract])) OR (Hashimoto Thyroiditis[Title/Abstract])) OR (Graves Disease[Title/Abstract])) OR (Hyperthyroidism[Title/Abstract])) OR (Hypothyroidism[Title/Abstract])) OR (TgAb[Title/Abstract])) OR (TPOAb[Title/Abstract])) OR (TRAb[Title/Abstract])) OR (Endocrine Comorbidities[Title/Abstract])) OR (Autoimmune diseases[Title/Abstract])) AND ((psoriasis[Title/Abstract]) OR (psoriatic[Title/Abstract]))
Embase	(thyroid:ab,ti OR thyroiditis:ab,ti OR 'hashimoto thyroiditis':ab,ti OR 'graves disease':ab,ti OR hyperthyroidism:ab,ti OR hypothyroidism:ab,ti OR tgab:ab,ti OR tpoab:ab,ti OR trab:ab,ti OR 'endocrine comorbidities':ab,ti OR 'autoimmune diseases':ab,ti) AND (psoriasis:ab,ti OR psoriatic:ab,ti)
Scopus	((TITLE-ABS-KEY (thyroiditis) OR TITLE-ABS-KEY (hashimoto AND thyroiditis) OR TITLE-ABS-KEY (graves AND disease) OR TITLE-ABS-KEY (hyperthyroidism) OR TITLE-ABS-KEY (hypothyroidism) OR TITLE-ABS-KEY (tgab) OR TITLE-ABS-KEY (tpoab) OR TITLE-ABS-KEY (trab))) AND (TITLE-ABS-KEY (psoriasis) OR TITLE-ABS-KEY (psoriatic))
Cochrane	(((Psoriasis) OR psoriatic) OR Pustulosis of Palms) AND (((((((Thyroid) OR Thyroiditis) OR Thyroiditides) OR Hashimoto Disease) OR Graves Disease) OR Hyperthyroidism) OR Hypothyroidism)). And chose literature published up to "2021/11/01". Then chose "Trials"

Table 1 Database source and retrieval strategy.

TPOAb: Thyroid peroxidase antibody; TgAb: Thyroglobulin antibody; TRAb: Thyroid stimulating hormone receptor antibody.

Study (Author)	Year	Country	Study design	No. Patients	No. Controls	Patients, % Female	Patients, mean age
Antonelli <i>et al.</i>	2006	Italy	Case-cont rol	80	400	45	57
Tsai <i>et al.</i>	2011	China	Case-cont rol	51800	207200	38.5	46.4
Peluso <i>et al.</i>	2011	Italy	Case-cont rol	108	318	52.8	39.9
Wu <i>et al.</i>	2012	American	Case-cont rol	25341	126705	48.4	48.9
Vassilatou <i>et al.</i>	2017	Greece	Case-cont rol	114	286	49.1	52.7
Kiguradze <i>et al.</i>	2017	Greece	Cross-sect ional	9654	846961	NA	NA
Haddad <i>et al.</i>	2017	Israel	Case-cont rol	3161	31610	53.4	58.4
Fallahi <i>et al.</i>	2017	Italy	Cohort	97	97	47.4	56
Alidrisi <i>et al.</i>	2019	Iraq	Case-cont rol	56	54	58.9	43.05
Wang <i>et al.</i>	2019	China	Cohort	162842	162842	45.5	45
Valduga <i>et al.</i>	2021	Valduga	Case-cont rol	60	60	66.7	54.5

Table 2 Characteristics of the included studies

Study (Author)	Definition of psoriasis	Definition of AITD	NOS score
Antonelli <i>et al.</i>	The criteria of Vasey and Espinoza	Serum levels of thyroid stimulating hormone and TgAb and TPOAb	7
Tsai <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM codes 242.9x, 244.9x	6
Peluso <i>et al.</i>	Classification of Psoriatic Arthritis study group criteria	Serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL, and Thyroid ultrasonography	7
Wu <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM codes 242.0, 245.2	7
Vassilatou <i>et al.</i>	Moll and Wright criteria	Serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL	7
Kiguradze <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM codes 245.2	6*
Haddad <i>et al.</i>	Clinical diagnosis from Clalit Health Services	Clinical diagnosis from Clalit Health Services	6
Fallahi <i>et al.</i>	Criteria of Vasey and Espinoza	Serum levels of TgAb or TPOAb > 100 IU/mL	6
Alidrisi <i>et al.</i>	Clinical diagnosis from Endocrine and Metabolism Center	Serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL	6
Wang <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM code 242, 242.0, 244, 246	8
Valduga <i>et al.</i>	Clinical diagnosis and measured by Psoriasis Area and Severity Index (PASI)	Hypothyroidism was detected, or when they need for thyroid hormone replacement therapy or positive of TPOAb with or without TgAb	6

Table 3 Characteristics of the included studies (2)

*This was a score based on the AHRQ evaluation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

ICD-9-CM: The International Classification of Diseases, Ninth Revision, Clinical Modification

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Study(Author)	Year	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall bias
Antonelli <i>et al.</i>	2006	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Tsai <i>et al.</i>	2011	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Peluso <i>et al.</i>	2011	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Wu <i>et al.</i>	2012	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Moderate risk	Moderate risk
Vassilatou <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Moderate risk
Kiguradze <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Moderate risk	Moderate risk
Haddad <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Fallahi <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Alidrisi <i>et al.</i>	2019	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Wang <i>et al.</i>	2019	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Valduga <i>et al.</i>	2021	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Moderate risk	Moderate risk

Table 4 Risk of bias for the 11 included studies based on the ROBINS-I tool




Figure 1 Flowchart for study screening

164x200mm (300 x 300 DPI)




Figure 2 Forest plot of the association between psoriasis and autoimmune thyroid disease

215x206mm (300 x 300 DPI)





Figure 3 Sensitivity analysis and publication bias

141x138mm (300 x 300 DPI)






Figure 4 A: Forest plots of psoriasis and hypothyroidism B: Forest plots of psoriasis and hyperthyroidism C: Forest plots of psoriasis and HT


117x162mm (300 x 300 DPI)



Random-effects REML model




Random-effects REML model




Random-effects REML model

Figure 5 A: Forest plots of psoriasis and GD B: Forest plots of psoriasis and TgAb C: Forest plots of psoriasis and TPOAb

123x169mm (300 x 300 DPI)



Random-effects REML model



Random-effects REML model

117x97mm (300 x 300 DPI)



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a meta-analysis.	1
ABSTRACT			
Abstract	2	The abstract included Objective, Design, Data sources, Eligibility criteria for selecting studies, Data extraction and synthesis, Results, Conclusions, PROSPERO registration number .	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	4
Objectives	4	Provide an explicit statement of the objective the review addresses.	5
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	5, Table 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Table 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	6
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	7, Figure 1
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	6
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	6
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	7, 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	7
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	6
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	6



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Table 2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table 4
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2-5
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	8,10,11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	8-9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Figure 3
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Figure 3
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Figure 2
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	13,14
	23b	Discuss any limitations of the evidence included in the review.	15
	23c	Discuss any limitations of the review processes used.	15
	23d	Discuss implications of the results for practice, policy, and future research.	15
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	×
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	×
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	16
Competing interests	26	Declare any competing interests of review authors.	16
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	×



PRISMA 2020 Checklist

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only

BMJ Open

The prevalence of autoimmune thyroid disease in patients with psoriasis: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055538.R2
Article Type:	Original research
Date Submitted by the Author:	09-Jan-2022
Complete List of Authors:	Zhang, Xiaochao; The Second Xiangya Hospital of Central South University, Dermatology; Central South University Zhang, Suhan; The Second Xiangya Hospital of Central South University, Dermatology; Central South University Wu, Ruifang; The Second Xiangya Hospital of Central South University, Dermatology; Second Xiangya Hospital, Dermatology Li, Siying; The Second Xiangya Hospital of Central South University, Dermatology; Second Xiangya Hospital, Dermatology Su, Yuwen; The Second Xiangya Hospital of Central South University, Dermatology; Second Xiangya Hospital, Dermatology Zhang, Peng; The Second Xiangya Hospital of Central South University, Dermatology; Second Xiangya Hospital, Dermatology
Primary Subject Heading:	Dermatology
Secondary Subject Heading:	Dermatology, Immunology (including allergy)
Keywords:	Thyroid disease < DIABETES & ENDOCRINOLOGY, IMMUNOLOGY, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5 The prevalence of autoimmune thyroid disease in patients with psoriasis: a
6 meta-analysis
7
8
9
10

11
12 Xiaochao Zhang^{1#}, Suhan Zhang^{1#}, Ruifang Wu¹, Siying Li¹, Yuwen Su^{1*}, Peng
13 Zhang^{1*}
14

15
16
17 1. Department of Dermatology, The Second Xiangya Hospital, Central South
18 University
19

20
21 # Both two authors contributed equally to this work.
22
23

24
25
26 * Correspondence to: Yuwen Su, Department of Dermatology, The Second Xiangya
27 Hospital, Central South University, 139th Renmin Middle Road, Furong district,
28 Changsha, Hunan, 410011, China
29

30
31 Phone: 086-13755116633 Email: suyuwen1963@csu.edu.cn
32

33
34
35 Peng Zhang, Department of Dermatology, The Second Xiangya Hospital, Central South
36 University, 139th Renmin Middle Road, Furong district, Changsha, Hunan, 410011,
37 China
38
39

40
41 Phone: 086-15874291251 Email: zhangpeng@csu.edu.cn
42

43
44 Running title: A meta-analysis of AITD and psoriasis
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective Psoriasis is a chronic inflammatory disease with autoimmune etiology. A possible link between psoriasis and autoimmune thyroid disease (AITD) has been suggested in some studies with inconsistent findings. This meta-analysis aims to determine the association between psoriasis and AITD.

Design A Meta-analysis of observational studies.

Data sources PubMed, EMBASE, Scopus, and the Cochrane Library were searched up to November 1st, 2021.

Eligibility criteria for selecting studies We included non-randomized studies, each with over 50 cases in every group, focusing on the rate of comorbidity between psoriasis and AITD.

Data extraction and synthesis Two independent reviewers screened the articles and extracted data. The restricted maximum-likelihood was applied to perform the meta-analysis. Odds ratio (OR) and 95% confidence intervals (CI) were pooled to compare the prevalence of AITD in psoriasis and control groups. Heterogeneity was assessed with I^2 statistic. The Newcastle-Ottawa Scale (NOS) and Agency for Healthcare Research and Quality (AHRQ) were applied for quality assessment. The risk of bias was assessed with ROBINS-I.

Results Eleven available studies with data on 253,313 patients with psoriasis and 1,376,533 controls were included. Meta-analysis showed that patients with psoriasis had a higher prevalence of AITD (OR = 1.76, 95% CI: 1.35 - 2.28, $Z = 4.25$, $p < 0.01$), especially loss-of-function disorder of the thyroid gland. Both TgAb positive rate (OR = 1.98, 95% CI: 1.27 - 3.10, $Z = 3.00$, $p < 0.01$) and TPOAb positive rate (OR = 2.15, 95% CI: 1.31 - 3.52, $Z = 3.05$, $p < 0.01$) were also increased in the psoriasis group compared

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

to the control group.

Conclusions Our study indicates that the rate of co-occurring AITD was significantly increased in patients with psoriasis. It suggests that the increased risk of AITD should be concerned in patients with psoriasis.

PROSPERO registration number CRD42020206005

Keywords: Psoriasis, Thyroid, Immunology

Strengths and limitations of this study

This is the first meta-analysis focusing on the risk of AITD for psoriasis patients, which included hypothyroidism, hyperthyroidism, subclinical hypothyroidism, subclinical hyperthyroidism, Hashimoto's thyroiditis, Graves' disease, TgAb positivity and TPOAb positivity.

All studies included were of moderate to high quality and were representative. All studies were published in recent years.

The heterogeneity in the pooled data cannot be ignored, and was not improved by subgroup analysis. However, meta-regression analysis identified the differences of sample size and scope of research on AITD among these studies as the potential sources of heterogeneity.

INTRODUCTION

Psoriasis is a chronic inflammatory disease with autoimmune etiology, affecting approximately 125 million people around the world.¹ The skin lesions of psoriasis occur mainly on the scalp, trunk, and exterior surfaces of the limbs, and manifest as erythema, plaques, and scales.² Apart from the impaired appearance and intense pruritus of the skin lesions, various comorbidities have a significant impact on the quality of life in patients with psoriasis.^{3 4} Among the comorbidities, autoimmune thyroid disease (AITD) has been characterized in patients with psoriasis. For patients with psoriasis who also develop complications, their management requires extra attention.⁵ Therefore, understanding the risk of other diseases on psoriasis has important clinical significance.

Autoimmune thyroid disease (AITD) is an inflammatory disease of the thyroid gland with the presence of thyroid autoantibodies, lymphocytic infiltration of thyroid parenchyma, and even thyroid dysfunction.⁶ Graves' disease (GD) and Hashimoto's thyroiditis (HT) are the two main clinical subtypes of AITD. GD is characterized by hyperthyroidism and the presence of thyroid-stimulating hormone receptor antibodies (TRAb) in serum, while HT is characterized by hypothyroidism and the presence of thyroid peroxidase antibodies (TPOAb) or Thyroglobulin antibodies (TgAb) in serum.⁷

Psoriasis and AITD share some common pathophysiological features, such as Th1-predominant adaptive immune reaction.⁶ Hence, the relationship between AITD and psoriasis has been hypothesized and studied. In 2006, Antonelli *et al.* first

1
2
3
4 reported that the prevalence of AITD in patients with psoriatic arthritis was
5
6 significantly higher than in the general population.⁸ However, the study reported by
7
8 Tsai *et al.*⁹ pointed that the association between psoriasis and AITD was limited. In
9
10 recent years, several observational studies regarding the association between psoriasis
11
12 and AITD were published in succession, but the results of the studies were
13
14 inconsistent.¹⁰⁻¹⁶ In addition, Karadag *et al.* reported that the commonly administered
15
16 acitretin treatment for psoriasis system treatment affects the levels of free T4 (thyroid
17
18 hormone).¹⁷ To address this discrepancy, we designed and performed a meta-analysis
19
20 with the existing evidence to assess the relationship between psoriasis and AITD and
21
22 provide guidance on the clinical management of psoriasis.
23
24
25
26
27
28

29 30 **METHODS**

31 32 **Search strategy**

33
34 The literature search was conducted through PubMed, EMBASE, Scopus, and
35
36 the Cochrane Library for relevant studies published before November 1st, 2021.
37
38 Detailed literature-search strategies of the databases are presented in Table 1.
39
40

41 42 **Inclusion and exclusion criteria**

43
44 The inclusion criteria for the studies included in our analysis were the following:
45
46 (1) The prevalence of AITD in patients with psoriasis/psoriatic arthritis and
47
48 non-psoriasis were studied; (2) The study was a cohort study, case-control study, or
49
50 cross-sectional study; (3) The observed indicators were at least one of the following
51
52 outcomes: the prevalence of hypothyroidism, hyperthyroidism, HT, GD, or the
53
54 positive rate of TPOAb, TgAb, or TRAb; (4) The number of patients with psoriasis
55
56
57
58
59
60

1
2
3
4 and the control group should be over 50. Drug-related studies, animal studies, reviews,
5
6 and conference abstracts were excluded from our analysis.
7
8

9 **Data extraction**

10
11 The specific process for analyzing the studies generated from the search was as
12
13 follows: record screening and data extraction were performed by two independent
14
15 authors (X Zhang and S Zhang) according to the above retrieval strategy. When
16
17 disagreements could not be resolved through consensus by the two authors, these
18
19 were referred to the third author (R Wu) and resolved through discussion. The
20
21 following information in the included studies was extracted: the name of the first
22
23 author, year of publication, country of origin, study design, sample size, the definition
24
25 of psoriasis and AITD, gender ratio, and mean age.
26
27
28
29
30
31

32 **Quality assessment**

33
34
35 The Newcastle-Ottawa Scale (NOS)¹⁸ was used to assess the quality of the
36
37 included cohort and case-control studies. The quality of the study was scored on three
38
39 dimensions: selection, comparability, and exposure/outcome. Studies that achieved
40
41 0-3, 4-6, 7-9 scores were considered of low, moderate and high quality respectively.
42
43 Additionally, the tools recommended by the Agency for Healthcare Research and
44
45 Quality (AHRQ)¹⁹ were used for the cross-sectional studies. Eleven items were
46
47 included in AHRQ. The study was assigned one point if the answer “Yes”, otherwise
48
49 no points were assigned. Studies that achieved 0-3, 4-7, and 8-11 points were
50
51 considered of low, moderate and high quality respectively. Moreover, the ROBINS-I
52
53 was used to assess the risk of bias.²⁰ The assessments were carried by two authors (X
54
55
56
57
58
59
60

Zhang and S Zhang), and checked by the third author(R Wu).

The meta-analysis was performed using Stata 16.0 software. We used odds ratios (OR) and 95% confidence intervals (CI) to describe the differences between patients with and without psoriasis. Differences were considered statistically significant when $p < 0.05$. The prediction interval was used to explore the prevalence of AITD in individuals with psoriasis. The I^2 statistic was used to evaluate heterogeneity as follows: $I^2 \leq 25\%$, no heterogeneity; $25\% \leq I^2 \leq 50\%$, mild heterogeneity; $50\% < I^2 \leq 75\%$, moderate heterogeneity; $I^2 > 75\%$, severe heterogeneity. The random effects model was applied throughout the analyses. Publication bias was assessed by funnel plot and Egger's test (Publication bias was considered when $p < 0.1$). Sensitivity analysis was performed to assess the stability of the meta-analysis by omitting one study in each turn. Univariate meta-regression analysis was used to investigate the sources of heterogeneity. The flow chart was drawn in Adobe Illustrator, and the forest plots, funnel plots, and Egger's test charts were drawn by Stata 16.0 software.

Patient and public involvement

No patients or members of the public were involved in this review.

RESULTS

Search results

After removing duplicate results, we identified 6380 published studies in the initial search: 6377 studies were included by searching through databases and three studies were harvested by manually searching the references of relevant studies. After screening the titles and abstracts, the remaining 42 studies underwent further full-text

1
2
3
4 screening. Eventually, 11 studies^{8-16 21 22} that met the inclusion criteria were included
5
6
7 in the final analysis (figure. 1).

8 9 **Study characteristics**

10
11 The basic characteristics of the included studies are shown in Tables 2 and 3. A
12
13 total of 253,313 patients with psoriasis and 1,376,533 control patients were included
14
15 in the analysis. Two of the studies were cohort studies, eight were case-controlled
16
17 studies, and one was a cross-sectional study.
18
19
20

21 22 **Quality of studies**

23
24 Overall, five studies were of high quality and six of moderate ones (Table 3). In
25
26 the studies checked with NOS (n=10), five studies were considered of moderate
27
28 quality because the control groups were not from the same community. The only
29
30 cross-sectional study checked with AHRQ was a moderate quality study as the
31
32 method for control of confounding was not clear. Based on ROBINS-I, all included
33
34 studies had moderate risk in overall bias (Table 4).
35
36
37
38
39

40 41 **Prevalence of AITD in patients with psoriasis**

42
43 Eleven studies provided available data on the prevalence of AITD in patients
44
45 with psoriasis. The meta-analysis showed that patients with psoriasis had a higher
46
47 prevalence of AITD than the controls (OR = 1.76, 95% CI: 1.35 - 2.28, Z = 4.25, *p*
48
49 <0.01). The prediction interval ranged from 0.79 to 2.73, and the heterogeneity was
50
51 severe ($I^2 = 92.72\%$).
52
53
54

55 56 **Heterogeneity analysis**

57
58 To investigate potential sources of heterogeneity, we firstly performed a
59
60

1
2
3
4 subgroup analysis by types of study design. The high rate of comorbidity between
5
6 psoriasis and AITD was also observed in the cross-sectional study strata (OR = 2.12,
7
8 95% CI: 1.55 - 2.89), and in the case-control study strata (OR = 1.75, 95% CI: 1.23 -
9
10 2.48, $Z = 3.14$, $p < 0.01$) but with heterogeneity remaining severe (figure. 2), which
11
12 indicated that inconsistency of the study designs was not the source of high
13
14 heterogeneity.
15
16
17
18

19 We further conducted a meta-regression analysis to explore the reason for
20
21 between-study heterogeneity. Seven variables were included in the regression model,
22
23 covering average age, sex ratio, nation (China or other countries), race (Caucasian or
24
25 non-Caucasian), sample size, clinical types of psoriasis (psoriasis vulgaris or psoriatic
26
27 arthritis), and scope of research on AITD (all studies were divided into two categories:
28
29 one focusing on the loss-of-function disorder of the thyroid gland alone and the other
30
31 focusing on both the loss-of-function disorder and hyperfunction disorder of the
32
33 thyroid gland). When the statistical significance was set as $p < 0.1$, sample size ($\beta =$
34
35 -0.40 , $S.E. = 0.20$, $p = 0.07$) and scope of research on AITD ($\beta = 0.45$, $S.E. = 0.15$, $p =$
36
37 0.02) were the potential sources of high heterogeneity.
38
39
40
41
42
43
44

45 We removed three studies^{8 13 21} outside the funnel plot and then conducted the
46
47 meta-analysis again. The results of the reanalysis also showed that patients with
48
49 psoriasis had a higher prevalence of AITD than the controls (OR = 1.34, CI: 1.20-1.50,
50
51 $Z = 5.07$, $p < 0.01$), but with moderate heterogeneity ($I^2 = 57.30\%$). The results
52
53 indicated that these three studies may have contributed to severe heterogeneity in the
54
55 previous analysis. The source of heterogeneity in the study of Antonelli *et al.* was that
56
57
58
59
60

1
2
3
4 all the patients were patients with psoriatic arthritis,⁸ and the prevalence of AITD in
5
6 patients with psoriatic arthritis may be higher than that of patients with psoriasis.²³
7
8
9 The source of heterogeneity in the study by Peluso *et al.* may have been due to the
10
11 control group being comprised of hospital staff rather than the general population.²¹
12
13
14 The source of heterogeneity in the study of Kiguradze *et al.* may lie in the fact that it
15
16 was a cross-sectional study.¹³ These three studies were not excluded because they had
17
18 little effect on the final results of the analysis.
19
20
21

22 **Sensitivity analysis and publication bias**

23
24
25 Omission of either of the included studies did not significantly change the
26
27 confidence interval of the combined effect (figure. 3A). Therefore, the results of the
28
29 analysis were considered reliable and stable. The funnel plot for the publication bias is
30
31 shown in figure. 3B. The results of Egger's test showed significant publication bias (p
32
33 = 0.036, figure. 3C). There was a possibility of exaggerating the association between
34
35 psoriasis and AITD.
36
37
38
39

40 **Psoriasis and thyroid function status**

41
42
43 Patients with psoriasis had a higher prevalence of hypothyroidism than the
44
45 controls (OR = 1.21, 95% CI: 1.12 - 1.30, $Z = 4.80$, $p < 0.01$) and no significant
46
47 heterogeneity was observed ($I^2 = 0.00\%$). Patients with psoriasis had a higher
48
49 prevalence of hyperthyroidism than the controls (OR = 1.20, 95% CI: 1.12 - 1.30,
50
51 $Z = 4.78$, $p < 0.01$) and no significant heterogeneity was observed ($I^2 = 0.00\%$, figure.
52
53
54
55
56 4A-B).

57
58 Additionally, a higher prevalence of subclinical hypothyroidism and subclinical
59
60

1
2
3
4 hyperthyroidism was observed in patients with psoriasis compared with the controls
5
6 (Subclinical hypothyroidism: OR = 2.24, 95% CI: 0.26 - 19.13, Z = 0.74, $p = 0.46$.
7
8 Subclinical hyperthyroidism: OR = 2.66, 95% CI: 0.70 - 10.07, Z = 1.44, $p = 0.15$).
9
10
11 However, the difference was not statistically significant (Supplementary figure. 1
12
13
14 A-B).

15 16 17 **Psoriasis and specific autoimmune thyroid diseases**

18
19 The prevalence of HT in patients with psoriasis and the controls was 0.215% and
20
21 0.199%, respectively. In comparison, the prevalence of GD in patients with psoriasis
22
23 and the controls was 0.443% and 0.405%, respectively. The prevalence of HT was
24
25 significantly higher in patients with psoriasis than the controls (OR = 1.88, 95% CI:
26
27 1.50 - 2.35, Z = 5.47, $p < 0.01$) and the heterogeneity was moderate ($I^2 = 55.98\%$). The
28
29 prevalence of GD was also higher in patients with psoriasis than the controls (OR =
30
31 1.02, 95% CI: 0.65 - 1.60, Z = 0.07, $p = 0.94$) and the heterogeneity was severe ($I^2 =$
32
33 92.78%). However, the difference was not statistically significant (figure. 4C, figure.
34
35 5A).
36
37
38
39
40
41
42

43 **Psoriasis and thyroid serological antibodies**

44
45 No studies provided data on the positive rate of TRAb in patients with psoriasis,
46
47 so we only included TgAb and TPOAb in the meta-analysis (figure. 5B-C). The
48
49 positive rate of TgAb was significantly higher in patients with psoriasis than the
50
51 controls (OR = 1.98, 95% CI: 1.27 - 3.10, Z = 3.00, $p < 0.01$) and the heterogeneity
52
53 was mild ($I^2 = 41.54\%$). The positive rate of TPOAb was significantly higher in
54
55 patients with psoriasis than the controls (OR = 2.15, 95% CI: 1.31 - 3.52, Z = 3.05, p
56
57
58
59
60

1
2
3
4 <0.01) and the heterogeneity was moderate ($I^2 = 56.27\%$).
5

6 **DISCUSSION**

7
8
9 To our knowledge, this is the first meta-analysis focusing on the risk of AITD for
10 psoriasis patients. The study by Khan *et al.* is the first meta-analysis of studies on the
11 association between AITD and the incidence risk of psoriasis.²⁴ By summarizing all
12 available evidence on the association between psoriasis and AITD, we found that the
13 prevalence of AITD, particularly HT, was higher in patients with psoriasis than the
14 control individuals. Additionally, elevated positive rates of TgAb and TPOAb were
15 also observed in patients with psoriasis. As psoriasis is a type of discosmetic
16 dermatosis and therefore likely to be of concern, patients with psoriasis are more
17 likely to be active about seeing a doctor regarding their condition than patients with
18 AITD. As such, we recommend that patients with psoriasis receive a thyroid-related
19 examination when they have suspicious AITD-related symptoms. By promoting early
20 diagnosis and treatment of AITD, patients may be able to avoid thyroid dysfunction.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Main findings**

41
42 The primary finding of this meta-analysis is that the prevalence of AITD is
43 increased in patients with psoriasis compared with the general population. However,
44 severe heterogeneity was observed. In order to determine whether or not the
45 inconsistency of the study designs was the primary source of heterogeneity, the
46 subgroup analysis based on different study designs was conducted. However, the
47 heterogeneity was not limited by subgroup analysis; hence the heterogeneity in this
48 meta-analysis was not caused by inconsistency of the study design. Through further
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 meta-regression analysis, we found that the differences in sample size and scope of
5
6 research on AITD among these studies might explain the high level of between-study
7
8 heterogeneity. Furthermore, the heterogeneity was improved when we focused on the
9
10 link of psoriasis with specific clinical characters of AITD, such as hypothyroidism,
11
12 hyperthyroidism, and the positivity rate of autoantibodies.
13
14
15

16
17 According to the definition of the study designs, an accurate cause-effect
18
19 relationship can only be demonstrated in cohort studies. The present study included
20
21 three types of study designs, including cohort, case-controlled, and cross-sectional
22
23 studies. Therefore, the results should be interpreted with caution. Additionally, it has
24
25 been demonstrated that the prevalence of HT in patients with psoriasis is elevated
26
27 compared with the controls. HT, a main clinical subtype of AITD, is generally
28
29 accompanied by hypothyroidism. An elevated frequency of hypothyroidism was also
30
31 observed in patients with psoriasis. Taken together, the current data indicates that
32
33 psoriasis may be closely associated with the loss-of-function disorder of the thyroid
34
35 gland.
36
37
38
39
40
41
42

43 **Common pathogenesis of psoriasis and AITD**

44

45 Both abnormal immunological reactions and underlying genetic risk can
46
47 contribute to the pathogenesis of psoriasis and AITD.^{25 26} These two diseases share
48
49 some autoimmune processes and susceptibility genes, which may explain the
50
51 concurrence of psoriasis and AITD. The predominant Th1 immune reaction has been
52
53 observed in patients with psoriasis,^{27 28} such as Th1 infiltration in involved tissues,
54
55 and high serum levels of Th1-prototype chemokines and cytokines (TNF- α , IFN- γ ,
56
57
58
59
60

1
2
3
4 and CXCL10), all of which are present in AITD.²⁹⁻³² Additionally, Th17-mediated
5
6 immune disorder has also been observed in psoriasis and AITD.^{33 34} The two diseases
7
8 share several predisposing genetic alleles or regions. For example, the genetic data
9
10 from 265 families with two or more autoimmune disorders have shown that the
11
12 PTPN22-R620W allele has a remarkable association with HT and a mild association
13
14 with psoriasis.³⁵ Additionally, other SNP variations in the PTPN22 gene have been
15
16 demonstrated to be indicators for evaluating the risk of psoriasis.^{36 37} IL12B has been
17
18 generally recognized as a psoriasis susceptibility gene,³⁸ an upstream variation of
19
20 which affects the phenotype of AITD in men.³⁹
21
22
23
24
25
26
27

28 **Implications for practice**

29
30 As information relating to patient medications was not provided by in the
31
32 original research, drug exposure may be a source of residual confounding in the
33
34 present study and a potential risk factor for concurrence of psoriasis and AITD, apart
35
36 from the reasons mentioned above. β -blocker, used to control thyrotoxicosis-related
37
38 symptoms, has been implicated in induction or exacerbation of psoriasis.^{40 41} In
39
40 addition, it has been reported that the administration of acitretin, a common drug for
41
42 the treatment of psoriasis, can lead to the reduction of free T4 (thyroid hormone)
43
44 levels in patients with psoriasis.¹⁷ Therefore, once the patients develop suspicious
45
46 symptoms after these treatments, diagnostic investigation and intervention should be
47
48 considered as early as possible to avoid the exacerbation. On the other hand, the
49
50 treatment for AITD and psoriasis can be mutually beneficial. For example,
51
52 propylthiouracil (PTU), a drug used to inhibit thyroid hormone synthesis, has been
53
54
55
56
57
58
59
60

1
2
3
4 effective in the treatment of psoriasis.⁴² Based on the above findings, it is
5
6 recommended that the treatment options be adjusted once patients with psoriasis are
7
8 diagnosed with comorbid AITD.
9
10

11 **Limitations**

12
13
14 There are several limitations to this meta-analysis. First, the meta-analysis
15
16 included studies with different study designs. Given this, we conducted a subgroup
17
18 analysis of each study design, which also showed that the patients with psoriasis had
19
20 an increased prevalence of AITD in the cross-sectional study strata and the
21
22 case-control study strata. Second, there is considerable heterogeneity in the present
23
24 study. Subgroup analysis and meta-regression analysis helped us to identify the
25
26 potential sources of the heterogeneity. However, there are likely to be other unknown
27
28 reasons responsible for the heterogeneity. Thirdly, the lack of information on drug
29
30 application made drug exposure a confounding factor. Therefore, further large-scale
31
32 and high-quality prospective studies are still required to validate our findings.
33
34
35
36
37
38
39

40 **CONCLUSIONS**

41
42
43 The present meta-analysis revealed that AITD was more prevalent in patients
44
45 with psoriasis than in the general population, especially loss-of-function disorder of
46
47 the thyroid gland. Moreover, patients with psoriasis were found to have elevated
48
49 positive rates of TPOAb and TgAb compared to the control individuals. Accordingly,
50
51 we recommend that every dermatologist be conscious of this association and suggest
52
53 necessary examinations and intervention be considered as soon as possible when
54
55 patients with psoriasis have suspicious AITD-related symptoms.
56
57
58
59
60

1
2
3
4 **Contributors** XZ and SZ carried out the extraction of reference data, meta-analysis,
5
6 and wrote manuscripts, RW and PZ supported and assisted the manuscripts, YS and
7
8 SL reviewed and suggested the manuscripts. All authors were involved in finalizing
9
10 the manuscript.
11
12

13 **Funding**

14
15 This work was supported by grants from the National Natural Science Foundation of
16
17 China (No. 82173427 to Yuwen Su), The “Xiangya Outstanding Doctor” Bonus and
18
19 the Fundamental Research Funds for the Central Universities of Central South
20
21 University (No. 2019zzts905).
22
23
24

25
26 **Competing interests** None declared.
27
28

29
30 **Patient consent for publication** Not required.
31

32
33 **Ethics approval** As this is a meta-analysis ethics approval was not required.
34

35
36 **Provenance and peer review** Not commissioned; externally peer reviewed.
37

38
39 **Data availability statement** All data relevant to the study are included in the article.
40

41
42 **Acknowledgments** Not required.
43

44 **ORCID iD**

45
46 Yuwen Su <https://orcid.org/0000-0001-9918-1830>
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Griffiths CEM, Van Der Walt JM, Ashcroft DM, *et al.* The global state of psoriasis disease epidemiology: a workshop report. *Br J Dermatol* 2017;177(1):e4-e7.
2. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis* 2005;64 Suppl 2:ii18-23; discussion ii24-5.
3. Dauden E, Castaneda S, Suarez C, *et al.* Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. *J Eur Acad Dermatol Venereol* 2013;27(11):1387-404.
4. Schaefer CP, Cappelleri JC, Cheng R, *et al.* Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. *J Am Acad Dermatol* 2015;73(4):585-93.e3.
5. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. *J Am Acad Dermatol* 2019;80(1):27-40.
6. Antonelli A, Ferrari SM, Corrado A, *et al.* Autoimmune thyroid disorders. *Autoimmun Rev* 2015;14(2):174-80.
7. Hesarghatta Shyamasunder A, Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves' disease. *Clin Endocrinol (Oxf)* 2017;86(5):652-57.
8. Antonelli A, Delle Sedie A, Fallahi P, *et al.* High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. *J Rheumatol* 2006;33(10):2026-8.
9. Tsai TF, Wang TS, Hung ST, *et al.* Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci* 2011;63(1):40-6.
10. Alidrisi HA, Al Hamdi K, Mansour AA. Is There Any Association Between Psoriasis and Hashimoto's Thyroiditis? *Cureus* 2019;11(3):e4269.
11. Fallahi P, Ferrari SM, Ruffilli I, *et al.* Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. *Immunol Res* 2017;65(3):681-86.
12. Haddad A, Ashkenazi RI, Bitterman H, *et al.* Endocrine Comorbidities in Patients with Psoriatic Arthritis: A Population-based Case-controlled Study. *J Rheumatol* 2017;44(6):786-90.
13. Kiguradze T, Bruins FM, Guido N, *et al.* Evidence for the association of Hashimoto's thyroiditis with psoriasis: a cross-sectional retrospective study. *Int J Dermatol* 2017;56(5):553-56.
14. Valduga JaG, Rebeiko LB, Skare TL. Prevalence of Hashimoto's thyroiditis in psoriasis patients. *Rev Assoc Med Bras (1992)* 2021;67(1):52-57.
15. Vassilatou E, Papadavid E, Papastamatakis P, *et al.* No association of psoriasis with autoimmune thyroiditis. *J Eur Acad Dermatol Venereol* 2017;31(1):102-06.
16. Wang SH, Wang J, Lin YS, *et al.* Increased risk for incident thyroid diseases in people with psoriatic disease: A cohort study. *J Am Acad Dermatol* 2019;80(4):1006-12.
17. Karadag AS, Ozlu E, Kostek O, *et al.* Effect of low-dose acitretin treatment on pituitary hormones in psoriasis vulgaris: A retrospective study. *Indian J Dermatol Venereol Leprol* 2019;85(3):300-04.
18. Wells. G, Shea. B, O'connell. D, *et al.* The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in Newcastle-analyses. 11th November 2021 2019. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
19. Rostom. A, Dubé. C, Cranney. A, *et al.* AHRQ Evidence Reports. 11th November 2021 2004. <https://www.ncbi.nlm.nih.gov/books/NBK35156/>.
20. Sterne JA, Hernán MA, Reeves BC, *et al.* ROBINS-I: a tool for assessing risk of bias in

- 1
2
3 non-randomised studies of interventions. *BMJ (Clinical research ed)* 2016;355:i4919.
- 4
5 21. Peluso R, Lupoli GA, Del Puente A, *et al.* Prevalence of thyroid autoimmunity in patients with
6 spondyloarthropathies. *J Rheumatol* 2011;38(7):1371-7.
- 7
8 22. Wu JJ, Nguyen TU, Poon KY, *et al.* The association of psoriasis with autoimmune diseases. *J Am*
9 *Acad Dermatol* 2012;67(5):924-30.
- 10
11 23. Vastarella M, Megna M, Lupoli GA, *et al.* Is there any association between psoriasis, psoriatic
12 arthritis and thyroid autoimmunity? *Australas J Dermatol* 2020.
- 13
14 24. Khan SR, Bano A, Wakkee M, *et al.* The association of autoimmune thyroid disease (AITD) with
15 psoriatic disease: a prospective cohort study, systematic review and meta-analysis. *Eur J*
16 *Endocrinol* 2017;177(4):347-59.
- 17
18 25. Perera GK, Di Meglio P, Nestle FO. Psoriasis. *Annual review of pathology* 2012;7:385-422.
- 19
20 26. Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of
21 pathogenesis. *Nature reviews Endocrinology* 2013;9(5):277-87.
- 22
23 27. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. *Cell Mol Immunol*
24 2012;9(4):302-9.
- 25
26 28. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. *Annu Rev Immunol*
27 2014;32:227-55.
- 28
29 29. Antonelli A, Ferrari SM, Giuggioli D, *et al.* Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune
30 diseases. *Autoimmun Rev* 2014;13(3):272-80.
- 31
32 30. Ruffilli I, Ragusa F, Benvenga S, *et al.* Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity.
33 *Front Endocrinol (Lausanne)* 2017;8:139.
- 34
35 31. Nanba T, Watanabe M, Inoue N, *et al.* Increases of the Th1/Th2 cell ratio in severe Hashimoto's
36 disease and in the proportion of Th17 cells in intractable Graves' disease. *Thyroid*
37 2009;19(5):495-501.
- 38
39 32. Peng S, Li C, Wang X, *et al.* Increased Toll-Like Receptors Activity and TLR Ligands in Patients with
40 Autoimmune Thyroid Diseases. *Front Immunol* 2016;7:578.
- 41
42 33. Hansel A, Gunther C, Ingwersen J, *et al.* Human slan (6-sulfo LacNAc) dendritic cells are
43 inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. *J*
44 *Allergy Clin Immunol* 2011;127(3):787-94.e1-9.
- 45
46 34. Vitales-Noyola M, Ramos-Levi AM, Martinez-Hernandez R, *et al.* Pathogenic Th17 and Th22 cells
47 are increased in patients with autoimmune thyroid disorders. *Endocrine* 2017;57(3):409-17.
- 48
49 35. Criswell LA, Pfeiffer KA, Lum RF, *et al.* Analysis of families in the multiple autoimmune disease
50 genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple
51 autoimmune phenotypes. *Am J Hum Genet* 2005;76(4):561-71.
- 52
53 36. Li Y, Liao W, Chang M, *et al.* Further genetic evidence for three psoriasis-risk genes: ADAM33,
54 CDKAL1, and PTPN22. *J Invest Dermatol* 2009;129(3):629-34.
- 55
56 37. Wang H, Wang Z, Rani PL, *et al.* Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk
57 genes demonstrates shared pathogenesis between psoriasis and diabetes. *Exp Dermatol*
58 2017;26(11):1112-17.
- 59
60 38. Cargill M, Schrodi SJ, Chang M, *et al.* A large-scale genetic association study confirms IL12B and
leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 2007;80(2):273-90.
39. Walsh JP, Berry J, Liu S, *et al.* The clinical presentation of autoimmune thyroid disease in men is
associated with IL12B genotype. *Clin Endocrinol (Oxf)* 2011;74(4):508-12.
40. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. *Psoriasis (Auckl)*

1
2
3 2017;7:87-94.

4 41. Mcdermott MT. Hyperthyroidism. *Annals of internal medicine* 2020;172(7):ITC49-ITC64.

5
6 42. Gnanaraj P, Malligarjunan H, Dayalan H, *et al.* Therapeutic efficacy and safety of propylthiouracil
7 in psoriasis: an open-label study. *Indian J Dermatol Venereol Leprol* 2011;77(6):673-6.
8
9

10
11
12 **Figure legend:**

13
14 Figure 1 Flowchart for study screening

15
16
17 Figure 2 Forest plot of the association between psoriasis and autoimmune thyroid
18 disease
19

20
21
22 Figure 3 Sensitivity analysis and publication bias

23
24
25 Figure 4 A: Forest plots of psoriasis and hypothyroidism B: Forest plots of psoriasis
26 and hyperthyroidism C: Forest plots of psoriasis and HT
27

28
29
30 Figure 5 A: Forest plots of psoriasis and GD B: Forest plots of psoriasis and TgAb C:
31 Forest plots of psoriasis and TPOAb
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Database	Retrieval strategy
PubMed	((((((((Thyroid[Title/Abstract]) OR (Thyroiditis[Title/Abstract])) OR (Hashimoto Thyroiditis[Title/Abstract])) OR (Graves Disease[Title/Abstract])) OR (Hyperthyroidism[Title/Abstract])) OR (Hypothyroidism[Title/Abstract])) OR (TgAb[Title/Abstract])) OR (TPOAb[Title/Abstract])) OR (TRAb[Title/Abstract])) OR (Endocrine Comorbidities[Title/Abstract])) OR (Autoimmune diseases[Title/Abstract])) AND ((psoriasis[Title/Abstract]) OR (psoriatic[Title/Abstract]))
Embase	(thyroid:ab,ti OR thyroiditis:ab,ti OR 'hashimoto thyroiditis':ab,ti OR 'graves disease':ab,ti OR hyperthyroidism:ab,ti OR hypothyroidism:ab,ti OR tgab:ab,ti OR tpoab:ab,ti OR trab:ab,ti OR 'endocrine comorbidities':ab,ti OR 'autoimmune diseases':ab,ti) AND (psoriasis:ab,ti OR psoriatic:ab,ti)
Scopus	((TITLE-ABS-KEY (thyroiditis) OR TITLE-ABS-KEY (hashimoto AND thyroiditis) OR TITLE-ABS-KEY (graves AND disease) OR TITLE-ABS-KEY (hyperthyroidism) OR TITLE-ABS-KEY (hypothyroidism) OR TITLE-ABS-KEY (tgab) OR TITLE-ABS-KEY (tpoab) OR TITLE-ABS-KEY (trab))) AND (TITLE-ABS-KEY (psoriasis) OR TITLE-ABS-KEY (psoriatic))
Cochrane	(((Psoriasis) OR psoriatic) OR Pustulosis of Palms) AND (((((((Thyroid) OR Thyroiditis) OR Thyroiditides) OR Hashimoto Disease) OR Graves Disease) OR Hyperthyroidism) OR Hypothyroidism)). And chose literature published up to "2021/11/01". Then chose "Trials"

Table 1 Database source and retrieval strategy.

TPOAb: Thyroid peroxidase antibody; TgAb: Thyroglobulin antibody; TRAb: Thyroid stimulating hormone receptor antibody.

Study (Author)	Year	Country	Study design	No.Patients	No.Controls	Patients, % Female	Patients, % mean age
Antonelli <i>et al.</i>	2006	Italy	Case-control 1	80	400	45	57
Tsai <i>et al.</i>	2011	China	Case-control 1	51800	207200	38.5	46.4
Peluso <i>et al.</i>	2011	Italy	Case-control 1	108	318	52.8	39.9
Wu <i>et al.</i>	2012	American	Case-control 1	25341	126705	48.4	48.9
Vassilatou <i>et al.</i>	2017	Greece	Case-control 1	114	286	49.1	52.7
Kiguradze <i>et al.</i>	2017	Greece	Cross-sectional	9654	846961	NA	NA
Haddad <i>et al.</i>	2017	Israel	Case-control 1	3161	31610	53.4	58.4
Fallahi <i>et al.</i>	2017	Italy	Cohort	97	97	47.4	56
Alidrisi <i>et al.</i>	2019	Iraq	Case-control 1	56	54	58.9	43.05
Wang <i>et al.</i>	2019	China	Cohort	162842	162842	45.5	45
Valduga <i>et al.</i>	2021	Valduga	Case-control 1	60	60	66.7	54.5

Table 2 Characteristics of the included studies

Study (Author)	Definition of psoriasis	Definition of AITD	NOS score
Antonelli <i>et al.</i>	The criteria of Vasey and Espinoza	Serum levels of thyroid stimulating hormone and TgAb and TPOAb	7
Tsai <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM codes 242.9x, 244.9x	6
Peluso <i>et al.</i>	Classification of Psoriatic Arthritis study group criteria	Serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL, and Thyroid ultrasonography	7
Wu <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM codes 242.0, 245.2	7
Vassilatou <i>et al.</i>	Moll and Wright criteria	Serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL	7
Kiguradze <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM codes 245.2	6*
Haddad <i>et al.</i>	Clinical diagnosis from Clalit Health Services	Clinical diagnosis from Clalit Health Services	6
Fallahi <i>et al.</i>	Criteria of Vasey and Espinoza	Serum levels of TgAb or TPOAb > 100 IU/mL	6
Alidrisi <i>et al.</i>	Clinical diagnosis from Endocrine and Metabolism Center	Serum levels of TgAb > 115 IU/mL or TPOAb > 34 IU/mL	6
Wang <i>et al.</i>	ICD-9-CM code 696.0	ICD-9-CM code 242, 242.0, 244, 246	8
Valduga <i>et al.</i>	Clinical diagnosis and measured by Psoriasis Area and Severity Index (PASI)	Hypothyroidism was detected, or when they need for thyroid hormone replacement therapy or positive of TPOAb with or without TgAb	6

Table 3 Characteristics of the included studies (2)

*This was a score based on the AHRQ evaluation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

ICD-9-CM: The International Classification of Diseases, Ninth Revision, Clinical Modification

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Study(Author)	Year	Bias due to confounding	Bias in selection of participants into the study	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported result	Overall bias
Antonelli <i>et al.</i>	2006	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Tsai <i>et al.</i>	2011	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Peluso <i>et al.</i>	2011	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Wu <i>et al.</i>	2012	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Moderate risk	Moderate risk
Vassilatou <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Moderate risk
Kiguradze <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Moderate risk	Moderate risk
Haddad <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Fallahi <i>et al.</i>	2017	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Alidrisi <i>et al.</i>	2019	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Wang <i>et al.</i>	2019	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Low risk	Moderate risk
Valduga <i>et al.</i>	2021	Moderate risk	Low risk	Low risk	Moderate risk	Low risk	Low risk	Moderate risk	Moderate risk

Table 4 Risk of bias for the 11 included studies based on the ROBINS-I tool




Figure 1 Flowchart for study screening

164x200mm (300 x 300 DPI)




Figure 2 Forest plot of the association between psoriasis and autoimmune thyroid disease

215x206mm (300 x 300 DPI)





Figure 3 Sensitivity analysis and publication bias

141x138mm (300 x 300 DPI)






Figure 4 A: Forest plots of psoriasis and hypothyroidism B: Forest plots of psoriasis and hyperthyroidism C: Forest plots of psoriasis and HT


117x162mm (300 x 300 DPI)



Random-effects REML model




Random-effects REML model




Random-effects REML model

Figure 5 A: Forest plots of psoriasis and GD B: Forest plots of psoriasis and TgAb C: Forest plots of psoriasis and TPOAb

123x169mm (300 x 300 DPI)



Random-effects REML model



Random-effects REML model

117x97mm (300 x 300 DPI)



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a meta-analysis.	1
ABSTRACT			
Abstract	2	The abstract included Objective, Design, Data sources, Eligibility criteria for selecting studies, Data extraction and synthesis, Results, Conclusions, PROSPERO registration number .	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	4
Objectives	4	Provide an explicit statement of the objective the review addresses.	5
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	5, Table 1
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Table 1
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	6
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	6
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	7, Figure 1
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	6
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	7
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	6
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	7, 8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	7
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	6
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	6



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Figure 1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure 1
Study characteristics	17	Cite each included study and present its characteristics.	Table 2
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Table 4
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Figure 2-5
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	8
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	8,10,11
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	8-9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Figure 3
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Figure 3
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Figure 2
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	13,14
	23b	Discuss any limitations of the evidence included in the review.	15
	23c	Discuss any limitations of the review processes used.	15
	23d	Discuss implications of the results for practice, policy, and future research.	15
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	2
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	×
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	×
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	16
Competing interests	26	Declare any competing interests of review authors.	16
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	×



PRISMA 2020 Checklist

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

For peer review only